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Abstract 
Introduction: Systemic lupus erythematosus (SLE) is a multi-system autoimmune 
disease of unknown aetiology. There is growing evidence environmental factor(s) 
trigger the disease in the genetically susceptible host. Fragment crystallisable 
receptor (FCR) genes encode receptors that recognise the fragment crystallisable 
(Fc) portion of immunoglobulins (IgG) play an important role in the removal of 
antigen-antibody complexes from the circulation. Genes that code for these receptors 
have shown to be associated with susceptibility to SLE in various populations. The 
aim of the present study is to determine the role of single nucleotide polymorphisms 
(SNPs), allotypes and copy number variations of FC Gamma receptor genes IIIA and 
IIIB in susceptibility for the Black South Africans with SLE. 
 
Methods: DNA from 162 Black South African SLE patients and 155 matched controls 
were investigated using Taqman assays to determine SNP genotyping differences 
(FCGRIIIA) and copy number variation (CNV) number (FCGRIIIB). A PCR was 
optimised in order to determine the allotype differences (FCGRIIIB) via agarose gel 
electrophoresis. Statistical analyses were then performed on the data to see if the 
results displayed significance in susceptibility to SLE. 
 
Results: The minor allele of the allotypes (FCGRIIIB) and the rs396991 SNP 
(FCGRIIIA) were not statistically significant in conferring susceptibility to SLE in 
cases or controls. The rs10127393 SNP (FCGRIIIA) was shown to be monomorphic 
within both cases and controls for the T allele and is not associated with SLE. The 
cumulative percentage of copy numbers (FCGRIIIB) ≤2 copies were 0.6% larger in 
cases than seen in controls. Although this was not significant, this was what has 
been previously suggested in the literature. Almost half of the cases (43.8%) had 
lupus nephritis (LN). Upon investigation the NA1/NA2 alleles were found to confer 
susceptibility to LN (p=0.018), whereas the rs396991 G allele did not (p=0.643). 
 
Conclusion: In this study the allotypes, SNPs and CNV investigated were not found 
to confer susceptibility to SLE. However, subtle trends suggest that further studies 
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are required with larger sample sizes to acquire more data. Almost half of the cases 
were diagnosed with LN and the NA2 allele was shown to be a risk factor in 
developing LN. 
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Chapter 1 
Introduction 
1.1.   Definition  
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease with 
varied clinical features. The disease itself is characterised by autoantibodies against 
nuclear antigens (Tsokos, 2011). These antibody-antigen immune complexes deposit 
into target tissues leading to inflammation and end-organ disease.  
 
1.2.   Prevalence and Population Dynamics 
SLE has a prevalence that ranges from 20-150 cases in every 100 000 people. 
European populations have a prevalence of 40-50 in 100 000 whereas non-European 
populations have a prevalence that is three to four times higher (Hopkinson et al., 
1994; Gill et al., 2003; Guerra et al., 2012; Tiffin et al., 2013). However, the incidence 
of SLE has tripled in the past few decades probably due to improved diagnostic 
measures (Bertsias et al., 2012). 
 
It has been found that people of African, Hispanic and Asian ancestry tend to have 
an increased prevalence. The prevalence of SLE in Afro-Caribbean women, as 
estimated in a study, is 206 in 100 000 people (D'Cruz, 2006). The affected patients 
tend to have greater vital organ involvement. Previous studies have shown greater 
cardiac and renal involvement in non-European (60%) than in European patients 
(31%) (Alarcon et al., 1999; Fernandez et al., 2007). Black South Africans have a 
prevalence of about 12 in 100 000 (Tikly et al., 1996). 
 
The ratio of people being affected with SLE with regard to gender is 9 females to 1 
male. The fact that females are more affected is most likely due to the fact that they 
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have two X chromosomes, containing genes linked to the immune system (Elkon and 
Santer, 2012). 
 
1.3. History of SLE 
SLE was first recognised during the Middle Ages, when the dermatological 
presentation of the disease was described. During the 13th century, a physician 
called Rogerius described the characteristic “butterfly rash” (Robinson et al., 2011). 
The first illustrations of SLE were published in the Atlas of Skin Diseases in 1856 by 
Ferdinand von Hebra (Bertsias et al., 2012). The term lupus was given in the 19th 
century, when the word, lupus (Latin for ‘wolf’) was used to describe the red pattern 
on the patients’ faces (Tsokos, 2011).  
 
In 1872, Moritz Kaposi considered lupus to be a multiphenotypic disease (Rudofsky 
and Lawrence, 1999). However, only in the 20th century was it discovered that the 
disease is in fact systemic and not localised to the skin. Sequira  (1903) suggested 
that the disorder may have a genetic link, and he reported on two affected siblings 
who were not twins. Gallo and Forde  (1966) wrongly proposed that the disease was 
inherited via a dominant gene and two years later Rowell and Burch  (1968) 
constructed mathematical analyses in order to support the hypothesis that SLE is 
genetically based. 
 
Human leucocyte antigen (HLA) research done in the 1970’s concluded that certain 
genes in the major histocompatibility complex (MHC) were linked to SLE, mainly the 
HLA class I B8, and this observation was supported by the addition of linkage and 
association studies (Sestak et al., 2011). Bias et al.  (1986) were the first group to 
perform a linkage study on human SLE.  It was found that the association is in fact 
stronger between HLA class II DR2 and DR3 (Millard and McGregor, 2001). The 
current picture supports the hypothesis that SLE is not dominantly inherited, but is a 
polygenic disease in which many genes at different loci interact in order to produce 
the final phenotype (Tan and Arnett, 1998). Some genes and specific alleles have 
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been identified as linked more to SLE disease susceptibility than others, although 
other factors such as sex and environment also impact the emergence of the disease 
 
1.4. Clinical Features 
The most common manifestations of SLE are cutaneous, arthritis and mild 
haematological derangements, however in severe disease the central nervous 
system, kidneys and lungs may be involved (Bronson et al., 2012) ( Figure 1.1). The 
aetiology of SLE is complex and it is caused by both genetic and environmental 
factors (Boackle, 2013).  
 
SLE presents with variable symptoms that affect many systems. Symptoms can be 
mild to severe and some patients may have an isolated form such as cutaneous 
lupus erythematosus which only affects the skin (D'Cruz, 2006).  
 
 
In 80% of cases, patients will experience joint pain, arthritis and stiffness as seen in 
rheumatoid arthritis. Skin lesions as well as puffy hands and feet are also a common 
Figure 1.1: The symptoms and clinical features present in systemic lupus erythematosus 
(SLE) (Rhodus et al., 1990). 
(Left) Symptoms may vary between individuals and many tissues and systems may be affected. 
(Right) The typical “butterfly” rash is present on the face of a female diagnosed with SLE.  
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presentation (Doria et al., 2006). The classic “butterfly” rash or malar rash is seen on 
the cheeks and nose, and it presents as a flat or elevated rash. Organ damage may 
occur due to persistent inflammation; 61% of SLE patients develop such organ 
damage within seven years of diagnosis. The most commonly affected organ 
systems to be damaged are neurological, musculoskeletal and renal (Gill et al., 
2003). 
 
1.5. Etiology of SLE  
 
1.5.1.  Genetic Risk Factors 
Many genes have been found to be linked with SLE using techniques such as 
candidate gene approaches and genome-wide association studies (GWAS). Genes 
both within and outside of the major histocompatibilty complex (MHC) have proven 
relevant genetic markers for SLE (D'Cruz, 2006). GWAS takes note of a marker that 
is always inherited with a disease within families. The marker and disease gene are 
therefore strongly linked. Twin pair studies are a good indicator that SLE has a 
genetic component. Monozygotic twins have a 25%-57% concordance rate of SLE 
whereas dizygotic twins have a 4% rate. Twelve percent of SLE patients have a first 
degree relative with SLE and 3% of SLE first degree relatives of probands will 
develop SLE compared to 0.3% of people with healthy probands (Tan and Arnett, 
1998).  
 
A candidate gene approach compares gene variations within SLE patients and 
controls in order to ascertain specific disease alleles (Sestak et al., 2007). Genes that 
have been found to be involved in SLE, predominantly function within the immune 
system (Figure 1.2). Murine genetic models have been created in order to determine 
genes that result in lupus-like disease. The most well studied model is the New 
Zealand hybrid model, in which the New Zealand black (NZB) mouse and New 
Zealand white (NZW) mouse develop lupus-like disease (Vyse and Kotzin, 1998). 
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1.5.2. Epigenetics 
Epigenetics refers to the physical alterations in the structure of DNA. These changes 
affect gene expression by either activating or inactivating genes via mechanisms 
such as methylation or acetylation (Tsokos, 2011). Epigenetics plays a major role in 
SLE. Evidence has shown high levels of hypomethylated DNA in T cells allowing 
increased activation of transcription and thus increased disease activity (Costa-Reis 
and Sullivan, 2013).  Hypomethylation or the inhibition of DNA methylation by drugs 
such as hydralazine and procainamide may result in drug-induced SLE. Certain 
methylation-sensitive genes, such as ITGAL, CD40LG, CD70 and PPP2CA, involved 
Figure 1.2: Chromosome loci and genes associated with SLE (Tsokos, 2011) 
The approximate locations on the chromosomes of the genes associated with SLE are depicted. The 
genes are divided into six categories according to the main known function of the gene. Each category 
is represented by a different colour. An additional category (gray) includes genes that do not belong in 
these functional groups. Chromosome loci with orange bars on both sides indicate large SLE-
associated loci.  
6 
 
in SLE have been shown to be hypomethylated, and therefore overexpressed, upon 
investigation (Tsokos, 2011). This overexpression has resulted in T cell autoreactivity 
contributing to SLE pathogenesis (AlFadhli, 2012, Sestak et al., 2007). Pro-
inflammatory immune genes such as TNF-α are regulated at a chromatin level and 
changes may result in inflammation of tissues and organs (Costa-Reis and Sullivan, 
2013). 
 
1.5.3. Environmental Risk Factors  
In the presence of certain susceptibility genes, there are external factors that can 
initiate SLE or worsen symptoms. Possible SLE triggers include viruses, ultraviolet 
radiation, smoking and certain drugs. The disease is more commonly seen in patients 
from urban areas rather than from rural areas. This suggests that particle pollution in 
the air is another trigger of the disease (Sestak et al., 2011). 
 
Previous research proposes a link between the Epstein-Barr virus (EBV) and a 
greater risk of developing SLE. The similarity between the viral nuclear antigen 1 and 
the SLE autoantigen Ro support this idea. Ultraviolet (UV) rays, found in sunlight, and 
smoking are known SLE triggers and smoking may further damage affected organs 
(Millard and McGregor, 2001). 
 
Hormones such as oestrogen are found in high levels in females, and the hormone is 
suggested to enhance autoimmunity, while androgens and progestins suppress the 
immune response (Mok and Lau, 2003). Blood samples of SLE patients show low 
levels of androgens in the body. In addition, SLE patients are able to convert 
androgens to oestrogen at high rates resulting in high oestrogen concentration in the 
body. The fact that women of child-bearing age are often diagnosed with SLE 
suggests strongly that oestrogen may act as a trigger (Tsokos, 2011).  Therefore, 
women with a high risk of developing SLE are advised to avoid oral contraceptives 
that contain oestrogen as they result in a 1.9 times higher chance of developing the 
disease (Sestak et al., 2007). 
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1.6.      Diagnosis 
The American College of Rheumatology (ACR) in 1971 developed eleven criteria in 
order to classify SLE in a clinical setting. Four of the eleven criteria must be present 
in order to make a positive diagnosis (Heinlen et al., 2007). 
 
Since 1971, the ACR criteria have been revised in 1982 and in 1997 as the original 
list involved too many cutaneous conditions and too few criteria for organ 
involvement (Tan et al., 1982; Hochberg, 1997). The Systemic Lupus International 
Collaborating Clinics (SLICC) formulated SLICC criteria in 2012 which further modify 
the ACR criteria in order to make the diagnosis highly reliable (Yu et al., 2014).  
 
In order to make diagnosis more reliable, sensitive, specific and more timeously, the 
ACR and SLICC criteria were combined into a single table in 2015 (Salehi-Abari, 
2015). Each SLE criterion is designated a certain amount of points (as seen in Table 
1.1). A patient with 4 points out of 16, has a definite SLE diagnosis, a patient with 
three points is suggestive of SLE, while two points suggests probable SLE. 
 
There are two major scoring systems to evaluate the activity of SLE in clinical 
studies. The most frequently used measurement of lupus activity is called the SLE 
Disease Activity Index (SLEDAI) (Arbuckle et al., 2003).  This index consists of 24 
criteria, of which 16 are clinical criteria and 8 are laboratory results.  These criteria 
are scored based on whether these manifestations are present or absent in the 
patient in the previous 10 days (Bertsias et al., 2012).   
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1.7. Prognosis and Treatment  
 
Historically SLE had a very poor prognosis and was often fatal. In 1955 SLE had a 
five year survival rate after diagnosis but recently with a better understanding of the 
disease, earlier diagnosis, better understanding of the genetics and novel treatments, 
this disease has a good prognosis of a 70% 10 year survival rate (Doria et al., 2006, 
Tsokos, 2011). Males tend to develop more severe SLE disease, which includes 
renal and neurological symptoms. This results in a lower survival rate than is seen in 
females (Robinson et al., 2011). 
Table 1.1: 2015 Revised ACR/SLICC criteria for the diagnosis of SLE (Salehi-Abari, 2015) 
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Mortality is mostly due to active SLE which results in renal, pulmonary and intestinal 
manifestations (Doria et al., 2006). Infection is also a large contributor to causes of 
death (Cervera et al., 2003). Infections include tuberculosis (TB), pneumonia, urinary 
tract infections (UTIs) and sepsis. Mortality is often higher in patients with renal 
involvement.  
 
There are few effective therapies available to treat SLE. Medications such as 
corticosteroids were used as treatment for SLE from the middle of the 20th century. 
However, currently, SLE patients are given corticosteroids, anti-malarials and 
immunosuppressant drugs depending on the severity of the disease and the affected 
organs. Immunosuppressant drugs such as Mycophenolate mofetil (MMF) are used 
after organ transplants to prevent tissue rejection and are effective in treating lupus 
nephritis (Sestak et al., 2011). It is now possible to develop more effective therapies 
with the recent discovery of genetic loci and pathways. In the last twenty years 
certain target biologic agents have been created such as monoclonal antibodies, 
protein inhibitors and signalling modulators. B cells, T cells, cytokines and 
complement pathways can be targeted in order to treat SLE (Sestak et al., 2011). 
Clinical trials are in progress that genotype specific genetic polymorphisms in order to 
create specific therapeutic agents. 
 
A drug called Rituximab, which is a human-mouse monoclonal antibody directed 
against CD-20 on B cells (D'Cruz, 2006), has been shown to be effective in a certain 
subset of patients, often if used in combination with MMF. The Food and Drug 
Administration (FDA) of the USA approved eculizumab in 2007 which acts against 
the complementary protein C5 (Navarra, 2008). In 2012, the FDA approved the drug 
Belimumab which is a human monoclonal antibody that inhibits BLyS, the B-
lymphocyte stimulator (Bronson et al., 2012).  Belimumab was shown to have 
significant effects within the first year of treatment. Cytokines initiate inflammatory 
effects, therefore effective treatments working against cytokines IL-10 and IL-18 
(Sestak et al., 2011) are available. In a study of six people with SLE who were 
treated with IL-10 antibody, the IL-10 levels within the patients decreased greatly and 
were sustained over six months. Thus, although there is no cure for SLE, certain 
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drugs are available that can offer relief and control symptoms. However, in South 
Africa, at present, these treatments are too costly and are not generally available to 
the public. 
 
1.8.      Pathogenesis  
The genes involved in SLE code for proteins involved in B and T cell function, 
antigen presentation, the type I interferon/toll-like receptor pathway, apoptosis and 
immune complex clearance (Deng and Tsao, 2010; Costa-Reis and Sullivan, 2013). 
Immune complexes function in immunoregulation which includes enhancement as 
well as suppression (Nimmerjahn and Ravetch, 2006). The absence of immune 
tolerance, surplus T helper cell load, faulty B cell activation and autoantibody 
production contribute to SLE pathogenesis (Mok and Lau, 2003). 
 
1.8.1. T and B cell Signalling 
Certain genes associated with SLE regulate the function and activation of B cells 
(BLK, BANK1 and LYN) and T cells (STAT4 and PTPN22) (Deng and Tsao, 2010, 
Guerra et al., 2012).  
 
SLE patients tend to have increased numbers of T cells and T helper cells. These T 
cells lead to increased secretion of inflammatory cytokines, activation of B cells and 
dendritic cells and tissue damage (Figure 1.3). These T cells undertake a rapid rate 
of apoptosis, thus further contributing to SLE pathogenesis (Guerra et al., 2012). 
 
Hyperactive B cells present autoantigens and produce pathogenic autoantibodies 
(Figure 1.3), thus inducing T helper cells and inhibiting T regulatory cells. This 
process leads to secretion of pro-inflammatory cytokines such as IL-10 and IL-23, 
which inhibits T regulatory cells. 
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1.8.2 TLR/IFN Signalling 
Toll-like receptors (TLRs) activate the production of type I interferons (IFN) (Elkon 
and Casali, 2008) (Figure 1.3). Type I interferons are powerful cytokines (IFNα and 
IFNβ) that mediate the T helper cell response, sustain activated T cells and lower the 
B cell activation threshold. Impairment of this pathway results in secretion of pro-
inflammatory cytokines and thus chronic inflammation (Guerra et al., 2012).  
 
       1.8.3. Autoantibody Production 
Autoantibody production is the major disease basis in SLE as well as raised levels of 
IgG antinuclear antibodies (Vyse and Kotzin, 1998). IgG antibodies are antibodies 
present in the body that bind to autoantigens on nuclei of mammalian cells such as 
double-stranded DNA, membrane phospholipids and nuclear proteins. Disease-
causing IgGs are produced by B cells and the disease involves the emergence and 
activation of both autoreactive T cells and B cells. Autoreactive cells become large as 
a result of antigen stimulation and act against own tissues or cells. 
 
     1.8.4. Immune Complex Clearance 
SLE patients have defective phagocytic cells that cannot clear immune complexes. 
Defective clearance results from inadequate phagocytosis of IgG2 and IgG3 
containing complexes. Allelic polymorphisms of the IgG receptor genes and ITGAM 
have been described. Some of the polymorphic alleles are associated with lower 
binding of the Fc portions of IgG2 and IgG3, and hence impaired clearance of 
immune complexes (Cui et al., 2013). 
 
 
 
       1.8.5. Apoptosis 
Apoptosis, programmed cell death, is defective in SLE and apoptotic cells are not 
efficiently removed by the immune system, leading to a further transformation of 
necrotic cell death (Costa-Reis and Sullivan, 2013). Apoptotic cells change their 
morphology and envelop self-antigens thus forming apoptotic blebs (Guerra et al., 
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2012). These blebs carry proteins on their surface which act as a further source of 
autoantigens. This triggers inflammatory cytokine and interferon-α production 
resulting in further inflammation. 
 
1.9.      SLE in South Africa  
SLE is considered rare in tropical Africa yet people with African ancestry living away 
from the tropics, such as African-Americans, have the highest prevalence rates of 
12.2 in 100 000, associated with a more aggressive disease (Tikly et al., 1996, 
Wadee et al., 2007). Literature regarding SLE in South Africa is limited, leaving a gap 
in current knowledge, and highlighting the need for future studies. 
Figure 1.3: The pathogenesis of SLE (Deng and Tsao, 2010). 
 
a. Abnormal processing and clearance of immune complexes and apoptotic blebs via phagocytic cells. 
b. TLR–IFN signalling Activated TLRs result in secretion of type I IFN cytokines.  
c. T-cell activation via cytokines (IFNα and IFNβ) results in hyperactivation of B cells that produce 
autoantibodies. 
 
Abbreviations: IFN= interferon; TLR= Toll-like receptor  
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Benitha and Tikly  (2007) conducted a study to ascertain the quality of life in 50 Black 
SLE South African patients. Questionnaires were distributed to these patients relating 
to functional disability and health related quality of life (HRQOL). It was found that 
both socioeconomic and ethnic factors influenced the quality of life in South African 
patients with SLE. Another important conclusion that came out of this research is that 
state funded healthcare is extremely under resourced which results in delayed 
diagnosis and therefore delayed therapy. This also impacts negatively on the quality 
of life for these patients, as some patients are unable to work without therapy and 
therefore a reduced income is being brought into these households (Harris et al., 
2011). 
 
In a developing, middle-income country such as South Africa the main causes of 
death in patients with SLE are infections, such as tuberculosis (TB) and pneumonia 
(45%), renal failure (26%) and CNS associated lupus (13%). Overall, infection and 
active lupus account for 92.3% of deaths in SLE patients (Patel and Mody, 2014). 
Renal involvement and severe inflammation of body tissue lining the lungs and heart 
are more common in Black patients (present in 70% of black patients) (Mody et al., 
1994). Renal involvement results when immune complexes deposit themselves within 
the glomerulus. This leads to progressive disruption of the glomerular basement 
membrane, leading to proteinuria, which will eventually progress to end stage renal 
disease if not treated (Bertsias et al., 2012). 
 
Dubula and Mody  (2015) led a study that showed that 167 SLE patients had 327 
hospital admissions. This study was conducted in a Durban hospital in South Africa 
over a 79 month period. The reasons for admissions were divided into two 
categories, one being due to active disease, which accounted for 66.7% of 
admissions and the second being due to infection. Infections included pneumonia, 
sepsis, urinary tract infections (UTIs) and TB. TB accounted for 13.5% of admissions 
in this study and it is found to be prevalent in SLE patients (Simmons et al., 2008). 
This infection rate is due to immune system abnormalities such as complement 
deficiencies as well as drug therapy. Since SLE is treated with immunosuppressive 
drugs, which result in a weakened immune system, patients are more susceptible to 
contracting TB (Wadee et al., 2007).  
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Tikly et al.  (1996) identified the autoantibodies present in Black South African 
patients. Ro antibodies were seen in 60.5% of patients, La antibodies in 28.4%, and 
Sm antibodies in 44.2%. Anti- ribonucleoprotein (RNP) antibodies are also more 
commonly found in Black patients compared to White patients (Tikly et al., 1996, 
Mody et al., 1994). 
 
In comparison to studies done on White patients it was shown that Black patients 
produce higher levels of La antibodies (31% in Black patients vs. 9% in White 
patients). Anti-dsDNA antibodies are frequent more often in Black patients (41%) 
than in White patients (21%) (Alarcon et al., 1999). 
 
The results of these studies propose that the disease outcome of SLE patients in 
Southern Africa is considerably worse than patients in better developed countries 
(Lalloo et al., 2004). The fact that Black patients tend to have a more aggressive 
disease course and that South Africa lacks suitable healthcare facilities causes a 
higher mortality rate  (Wadee et al., 2007). This situation again highlights the need for 
further studies to be conducted in South Africa to better understand the pathogenesis 
and genetics of the disease. 
 
1.10.       FC Gamma Receptor IIIA and IIIB Genes  
Fragment crystallisable receptor (FCGR) genes encode a structurally and functionally 
diverse family of receptors that recognise the fragment crystallisable (Fc) portion of 
immunoglobulins (IgG) and enable the effectiveness of antibody-antigen interactions 
(Brown et al., 2007, AlFadhli, 2012). 
 
Fc gamma receptors recognise immunoglobulin G (IgG) antibodies and are involved 
in the interaction and removal of antigen-antibody immune complexes by phagocytic 
cells, mainly macrophages (Brown et al., 2007, Tan and Arnett, 1998). Other 
functions include enhancement of antigen presentation, antibody-dependent cell-
mediated cytotoxicity (ADCC), degranulation, regulation of antibody production and 
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inflammatory cell activation (Gessner et al., 1998). These receptors play a role in 
SLE susceptibility as well as lupus nephritis (Tsao, 2004). 
 
There are three classes of Fc gamma receptors: FCGRI, FCGRII and FCGRIII, 
encoded by eight genes (Brown et al., 2007). These genes can be subdivided into 
isoforms such as FCGRIIA, FCGRIIB, FCGRIIIA, FCGRIIIB and FCGRIIIC (Figure 
1.4). This dissertation focuses solely on the isoforms FCGRIIIA and FCGRIIIB. 
 
Fc gamma receptors can be classified into high or low affinity receptors based on 
their affinity for the monomeric IgG antibody or they can be classified into either 
activating or inhibitory receptors based on their signalling activity and functions. The 
receptors transmit their signals via immunoreceptor tyrosine-based activation (ITAM) 
or inhibitor motifs (ITIM) (Nimmerjahn and Ravetch, 2006). Receptor functions 
include phagocytosis, B cell activation, cytokine production and immune complex 
uptake and clearance (Morgan et al., 2006; AlFadhli, 2012; Costa-Reis and Sullivan, 
2013). Both FCGRIIIA and FCGRIIIB are activating receptors and bind IgG1 and 
IgG3 differentially (Figure 1.5). IgG3 is bound with greater affinity. 
Figure 1.4: The Fc gamma receptor gene cluster on Chromosome 1q21: a susceptibility 
locus for SLE (Pradhan et al., 2008). 
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FCGRIIIA receptors are present on monocytes, macrophages, cytotoxic lymphocyte 
cells and dendritic cells, whereas FCGRIIIB receptors are present on neutrophils and 
a subset of basophils (Lehrnbecher et al., 1999). FCGRIIIB is unique in its 
attachment to the cell via a glycosylphosphatidylinositol (GPI) anchor, whereas other 
Fc gamma receptors are attached to the cell membrane via ligand binding α chains 
and/or signal transducing β chains (Nimmerjahn and Ravetch, 2008). This 
attachment variation occurs via an amino acid change at position 203 from a 
phenylalanine to a serine (Ravetch and Kinet, 1991). Variations in these genes have 
been found to lead to ineffective clearance of immune complexes from the circulation 
therefore resulting in deposition in tissues contributing to inflammation (AlFadhli, 
2012). The lower ability to remove immune complexes from the circulation can affect 
disease progression and outcome. Immune complexes are mostly cleared from the 
spleen and liver (Manger et al., 2002). In previous studies, Fc gamma receptors have 
been shown to be involved in autoimmune diseases as well as immune dysregulation 
(Hart et al., 1983; Tsokos, 2001; Rioux and Abbas, 2005; Rhodes and Vyse, 2008). 
 
Allelic variation and copy number variation within these genes have been found to 
confer variable risk for SLE in Caucasian and Hispanic patients (Brown et al., 2007, 
Mok and Lau, 2003). Variation has also been shown to affect disease progression 
and presentation, not only disease susceptibility (Pradhan et al., 2010; Costa-Reis 
Figure 1.5: The three classes of Fc gamma receptors. 
 
The red block highlights Fc gamma receptors IIIA and IIIB. FCGRIIIA is attached to the cell surface 
via α and β chains whereas FCGRIIIB is attached via a GPI anchor. Both receptors are activating in 
function and low in affinity to IgG1 and IgG3 (Vogelpoel et al., 2015). 
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and Sullivan, 2013). However, there are very few data for Black South African SLE 
patients at the Fc gamma receptor locus (Lassauniere and Tiemessen, 2016). 
 
1.10.1. FCGRIIIA 
Two missense single nucleotide polymorphisms (SNP) are present within the 
FCGRIIIA gene. The FCGRIIIA SNP (rs10127939) is a tri-allelic and the SNP 
(rs396991) is a bi-allelic polymorphism (Lehrnbecher et al., 1999).   
 
The rs10127939 tri-allelic single nucleotide polymorphism results in either a thymine 
to adenine or guanine base change at position 230 (c. 230T>G>A). This base 
change will also result in an amino acid change at position 48 (p. L48R/H). A tri-allelic 
SNP exists when three different base variations coexist within a population. This SNP 
was first described by de Haas et al.  (1996) and is found in the membrane distal 
IgG-like domain of FCGRIIIA (Koene et al., 1997). 
 
The 48H allele is linked to the severe immunodeficiency of natural killer (de Vries et 
al., 1996). These authors describe a patient who suffered from recurrent viral 
respiratory tract infections who was found to have a base change from T to A at 
position 230 in both alleles, resulting in a leucine to histidine amino acid change at 
position 48 (de Vries et al., 1996). 
 
Jawahar et al.  (1996) also identified a patient with recurrent herpes infection to have 
reduced circulation of cytotoxic lymphocyte cells. This patient was homozygous for 
the 48H allele. Cytotoxic lymphocyte cells perform a role in protection against viruses 
and bacteria and therefore play an important part in infection rates. This is significant 
as infections are commonly seen in Black South African SLE patients and therefore 
this SNP may be linked.  
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However, in past SLE studies the 48L allele was more frequently seen in SLE 
patients than in controls (Koene et al., 1998). Interestingly, linkage has been shown 
between the rs396991 176F allele and the rs10127939 48L allele in SLE patients. 
This may be due to the link between the IgG binding of these polymorphisms as 176F 
and 48L bind less efficiently (Koene et al., 1997, de Haas et al., 1996). In most cases 
176V/V is seen together with 48H/H, whereby a study was done on two children with 
recurrent infections. Upon genotyping these individuals were both found to be 
homozygous for the 176V and 48H alleles (de Vries et al., 1996; Koene et al., 1997; 
Van der Pol and Van de Winkel, 1998).   
 
The genotype frequencies of rs10127939 in Caucasian SLE patients is TT (78.7%), 
TG (7.3%), TA (12.8%), GG (0.4%), AG (0.4%) and AA (0.5%). The genotype 
frequencies in African American SLE patients is TT (94.3%), TG (2.3%), TA (2.9%), 
GG (0.0%), AG (0.2%) and AA (0.3%) (Dong et al., 2014). 
 
The allele frequencies in Caucasian control studies have found T at 0.86, G at 0.06 
and A at 0.08 (de Vries et al., 1996, de Haas et al., 1996). On the genetic variation 
database, dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/), the allele 
frequencies of this SNP are given for various populations. In the Yoruba population, 
the T allele is found at 0.91, G at 0.09 and the A at 0.00. This strongly suggests that 
the A allele may not be present within the South African Black population. However, 
no data exist on allele or genotype frequencies in the healthy Black South African 
population.  
 
The rs396991 single nucleotide polymorphism results in a thymine to guanine base 
change at position 559 (c. 559T>G). This will also result in an amino acid change at 
position 176 (p. F176V). This SNP was first described by Wu et al.  (1997) and is 
found in the membrane- proximal IgG-like loop of FCGRIIIA (Koene et al., 1997). 
 
The low affinity phenylalanine allele (176F) results in reduced binding capacity of the 
receptor to certain IgG antibody subclasses to clear immune complexes such as 
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IgG1 and IgG3 thus resulting in increased inflammation (Tanaka et al., 2005; Li et al., 
2009; Deng and Tsao, 2010; Sestak et al., 2011). 176F does not have the capacity to 
bind IgG4 (Li et al., 2014). Individuals homozygous for 176F/F were found to have 
higher titres of anti-dsDNA antibodies (Lee et al., 2002). 
 
The higher affinity valine allele (V176) binds more efficiently to IgG1, IgG3 and IgG4 
immune complexes resulting in more effective clearance (Karassa et al., 2003; Li et 
al., 2014).  176V/V cells have increased calcium influx, greater CD25 expression and 
more efficient apoptosis  (Li et al., 2014). 
 
The 176F allele confers a 1.2 fold risk increase for developing lupus nephritis in 
Europeans, Africans and Asians, as immune complexes deposit in renal glomeruli 
(Alarcon et al., 1999; Karassa et al., 2003; Kyogoku et al., 2004; Alizadeh et al., 
2007; Brown et al., 2007; Sestak et al., 2011). Previous studies have shown that this 
allele has a strong association with lupus nephritis in African Americans and SLE in 
Caucasians, thus highlighting the impact it has on SLE (Gessner et al., 1998; Koene 
et al., 1998; Seligman et al., 2001; Edberg et al., 2002; Karassa et al., 2003; Sullivan 
et al., 2003; Dong et al., 2014). A study found that the 176F allele has a strong 
association with SLE and lupus nephritis in Asian patients (Kyogoku et al., 2002; Li et 
al., 2010).  Caucasian studies have shown that the 176F/F genotype is associated 
with arthritis and serositis disease symptoms (Dijstelbloem et al., 2000). The 176V 
allele has been shown to have a protective effect against lupus nephritis (Lee et al., 
2003). This is interesting as the 176V allele is more commonly seen in Caucasians 
and they tend not to suffer from lupus nephritis as greatly as non-Caucasians (Zuniga 
et al., 2001; Fernandez et al., 2007). 
 
This association is not seen in rheumatoid arthritis studies; hence it may not be a 
susceptibility locus for all autoimmune diseases. In fact there has been an 
overrepresentation of the 176V allele in rheumatoid arthritis patients in previous 
studies (Kastbom et al., 2005). However, a link has been found between the 176F 
allele and SLE in Spanish rheumatoid arthritis patients (Nieto et al., 2000), but no 
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association has been found between this SNP and SLE in Mexican patients 
(Brambila-Tapia et al., 2011). 
 
A previous study conducted on Korean SLE patients by Lee et al. (2003) found that 
the frequency of GG homozygotes was observed at 15.4%, TT homozygotes were 
seen at 30.1% and TG heterozygotes at 54.5%. These data were also supported by 
a study done by Yun et al.  (2001). However, in both studies no association was 
found between the 176F allele and SLE. 
 
A study on African American SLE patients saw GG homozygotes at 8%, TT 
homozygotes at 42% and TG heterozygotes at 50%. Caucasian SLE patients were 
seen at GG (11%), TT (50%) and TG (39%) (Lehrnbecher et al., 1999, van der Pol 
and van de Winkel, 1998). 
 
In summary, GG homozygotes are seen at a lower frequency in African Americans 
than are seen in Caucasians and Asians correlating with the higher frequency of 
lupus nephritis in African Americans as the G allele is protective against lupus 
nephritis. TT homozygotes are seen at a higher frequency in Caucasians than are 
seen in African Americans and Asians. 
 
The genotype frequency, as seen in the healthy Black South African population, is TT 
(39.7%), TG (50%) and GG (10.3%). The allele frequency of T is 0.63 and G is 0.37 
(Lassauniere and Tiemessen, 2016). Another study using Caucasian controls found 
allele frequencies of T and G to be 0.74 and 0.26 respectively (Koene et al., 1998, 
Lehrnbecher et al., 1999). A previous study by Cunniffe  (2011) using Black South 
African SLE patients could not find an association between the rs396991 SNP and 
SLE susceptibility. However, the study sample size of patients and controls was small 
and other techniques, pyrosequencing and High Resolution Melt Analysis, were 
chosen for genotyping, which may have proven unreliable. On the genetic variation 
database, dbSNP, the allele frequencies of this SNP are given for various 
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populations. In the Yoruba population the G allele is found at 0.04 and the T allele at 
0.96. 
 
In summary, these SNPs (rs10127939 and rs396991) result in reduced efficiency of 
the monocytes and macrophages to clear IgG immune complexes and both SNPs 
have been found to have strong associations with SLE in African Americans.  
 
1.10.2. FCGRIIIB 
Two allelic variants or alloantigens are present within exon 3 of FCGRIIIB, namely 
FCGRIIIB-NA1 and FCGRIIIB-NA2. These alleles differ by 5 nucleotides causing a 
change of 4 amino acids. This results in four N-linked glycosylation sites in NA1 
(FCGRIIIB*01), whereas NA2 (FCGRIIIB*02) has six sites (Brown et al., 2007; Moritz 
et al., 2008; Willcocks et al., 2009). The molecular weight of NA1 is 50-65 kD 
whereas NA2 is 65-80kD. The difference in molecular weight is most probably due to 
the different glycosylation patterns (Bux et al., 1997).  
 
A third allele, SH, has been described in the literature. SH differs from NA2 by a 
single nucleotide change of a cytosine to an adenine at position 266 (Lehrnbecher et 
al., 1999). SH occurs in Caucasians at 4% and in Africans at 15% (Kissel et al., 2000; 
Kyogoku et al., 2004). This translates to there being three copies of the FCGRIIIB 
gene in some individuals (Brown et al., 2007, Lehrnbecher et al., 1999). Each gene 
will express a combination of NA1, NA2 and SH in these cases (Bux et al., 1997, 
Moritz et al., 2008). Kyogoku et al. (2004) found a similar SH allele frequency in 
Caucasian patients as seen in healthy Causcasians of other studies. This study 
concluded that the function of SH is still unknown, but it is thought to not be 
associated with SLE. However, given how prevalent this allotype is in Africans as 
compared to Caucasians, the study provides strong rationale to investigate SH in the 
South African population and its possible association with SLE. However, this 
allotype was not investigated in this study. 
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A small percentage of the European population (0.1%) and African population (2%) 
do not display either NA1 or NA2 on their neutrophils and are said to be NA-null, 
whereby they are deficient in the FCGRIIIB gene (Muniz- Diaz et al., 1995; Kissel et 
al., 2000; Matsuo et al., 2000; Siriboonrit et al., 2003; Kyogoku et al., 2004; Willcocks 
et al., 2008).  The Asian population has been shown have no NA-null individuals 
(Kyogoku et al., 2004). These individuals rarely show any signs of autoimmune 
disease and do not suffer from repeated bacterial infections. These individuals may 
however cause alloimmune neutropenia in their neonate (Clark et al., 1990; de Haas 
et al., 1995; Bux et al., 1997; Fanciulli et al., 2007; Moritz et al., 2008). Information 
regarding NA-null individuals in other ethnic groups is lacking. 
 
The NA2 allele is associated with low function and results in reduced binding efficacy 
of antigen-antibody complexes and lower phagocytic capacity, whereas the NA1 
allele binds IgG1 and IgG3 more efficiently (Gessner et al., 1998; Hatta et al., 1999; 
Lehrnbecher et al., 2000; Tanaka et al., 2005; Morris et al., 2010). NA1 possesses a 
higher phagocytic capacity and increases neutrophil- mediated phagocytosis (Salmon 
et al., 1990; Bredius et al., 1994) 
 
Previous Asian studies have found that the NA1 allele is overrepresented at a 
frequency of 0.66, whereas the NA2 allele is underrepresented at a frequency of 0.34 
(Rascu et al., 1997). The NA2 allele has been shown to be a susceptibility allele for 
SLE in Asians (Li et al., 2009, Siriboonrit et al., 2003). 
 
Contrary to that Asian report, the NA2 allele is more commonly seen in Caucasians 
at 0.7 whereas NA1 is seen at 0.3 (Van de Winkel and Capel, 1993; Muniz- Diaz et 
al., 1995; Bux et al., 1997; Hatta et al., 1999; Lehrnbecher et al., 1999; Edberg et al., 
2002; Gonzalez-Escribano et al., 2002; Kelly et al., 2002; Hong et al., 2005; Brown et 
al., 2007; Moritz et al., 2008; Nielsen et al., 2012).  
 
The NA1 allele is over represented in the healthy Black South African population and 
its frequency is 0.51, the NA2 allele occurs at a frequency of 0.34 and SH at a 
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frequency of 0.16 in healthy Black individuals (Lassauniere and Tiemessen, 2016). 
However, studies on other African populations show the NA1 allele to be at a 
frequency of 0.32 and NA2 at 0.68 (Hessner et al., 1996; Hessner et al., 1999; 
Lehrnbecher et al., 1999; Kissel et al., 2000; Matsuo et al., 2000; Moritz et al., 2008). 
 
FCGRIIIB is highly expressed and there are 150 000- 200 000 receptors per 
neutrophil (Li et al., 2009). A low copy number of the FCGR3B gene reduces 
FCGR3B membrane expression on neutrophils and results in decreased clearance of 
immune complexes (Breunis et al., 2009; Boackle, 2013). A copy number of less than 
two is associated with SLE, lupus nephritis, higher autoantibody titres and higher 
disease activity scores (SLEDAI), predominantly in Caucasians (Aitman et al., 2006; 
Fanciulli et al., 2007; Hollox et al., 2009; Li et al., 2009; Morris et al., 2010; Mueller et 
al., 2013; Nossent et al., 2013). Statistical analysis has found association between 0 
to 1 FCGRIIIB copies and SLE (OR= 1.59; p=9.1 x 10-7) (McKinney and Merriman, 
2012). In fact, it has been shown that ≥2 copies of FCGRIIIB have a protective effect 
against autoimmune disease (Tiffin et al., 2013, McKinney and Merriman, 2012). A 
median copy number of two is found in most study controls (Fanciulli et al., 2007). In 
a previous study the SLE cases were shown to have an average copy number of 1.9, 
whereas controls had an average copy number of 2.1 (Morris et al., 2010).  
Lassauniere and Tiemessen (2016) found that copy number variation (CNV) within 
FCGRIIIB is at a frequency of 26% in the South African Black population. Black 
individuals were found to have one gene copy of FCGRIIIB at 7.6%, two gene copies 
at 74%, three gene copies at 15.3% and four gene copies at 3.1%.  
 
1.11.     Clinical Variables 
Clinical variables will be investigated according to gender, age of onset, the SLICC 
disease index, presence of certain autoantibodies, the levels of the C3 and C4 
complement proteins that may result in hypocomplementemia (low levels of both C3 
and C4), presence or absence of lupus nephritis and previous tuberculosis infection. 
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1.12.    Study Objective and Aims  
The primary objective of this study is to determine if single nucleotide polymorphisms 
(SNPs), allotypes and copy number variation, present within the Fc gamma receptor 
genes IIIA and IIIB, contribute to the susceptibility of systemic lupus erythematosus 
(SLE) within the Black South African population. The three specific aims are:   
 
Aim 1: To ascertain if there is a significant association with the various SNPs, 
allotypes and copy number variation and the SLE phenotype. 
 
Aim 2: To ascertain if there is a significant association of the various SNPs, allotypes 
and copy number variation with clinical variables with particular interest in lupus 
nephritis. 
 
Aim 3: To ascertain the association of the various genetic variants with an increased 
risk of infections, including tuberculosis (TB) in Black South Africans with SLE. 
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Chapter 2 
Subjects and Methods 
2.1.    Subjects 
2.1.1. Patients 
A total of 162 consenting black South African patients from the Chris Hani 
Baragwanath Academic Hospital (CHBAH), >18 years of age at disease onset and 
fulfilling the 1997 American College of Rheumatology classification criteria 
(Hochberg, 1997) for SLE were included in the sample. Only patients with four or 
more SLICC (Systemic Lupus International Collaborating Clinics) criteria (Heinlen et 
al., 2007) have been included. Patients were considered as Black, if they reported 
that all four of their grandparents were ‘Black South Africans’. 
 
Certain clinical and laboratory information on the patients was documented at the 
time of blood collection. This information included: gender and age of the patient, age 
at the time of disease onset, the number of SLICC criteria present, TB status, C3 and 
C4 levels, the presence of anti-dsDNA and anti-Sm antibodies and the grade of lupus 
nephritis, if present. The stage of lupus nephritis was determined by a renal biopsy. 
Other information was acquired via blood test results and by consulting with the 
patient. The Human Research Ethics Medical Committee of the University of the 
Witwatersrand gave ethics clearance with ethics clearance certificate number 
M150624 (Appendix A). 
 
2.1.2. Controls 
A total of 155 healthy control samples matched to the experimental group in age, 
ethnicity and gender, who display no symptoms of SLE were used for comparison. 
Blood samples collected from these controls have been used in previous 
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autoimmune studies (Govind et al., 2014). These DNA samples are stored in the 
Division of Human Genetics, National Health Laboratory Service. 
 
Quanto (USC Biostats) was used to calculate the power of this study, and it was 
found to be 48%, whereas the preferred power would be 80%. However, the markers 
that are being investigated may function in a dominant or recessive manner whereas 
this power calculation assumes an additive model. The fact that the power of this 
study is low does not mean that significant associations will not be detected. 
Information regarding the second SNP is not available and if this SNP has a minor 
allele frequency (MAF) of 5%, the study may be more adequately powered. 
 
To increase the power of the findings a total of 317 samples (162 patients and 155 
controls) were investigated. Only patients who have been informed of the research 
and who have signed consent forms for the retrieval and use of their blood samples 
(Appendix B) were included in this study. Patients were excluded if they are not of 
African ethnicity or if they had mixed ancestry as lupus presents with different 
severities in other ethnicities. 
 
2.2.  Clinical Variables 
Clinical variables that were investigated included gender, age of disease onset, the 
SLICC disease index, presence of anti-dsDNA and anti-Sm antibodies, the levels of 
the C3 and C4, presence or absence of lupus nephritis and previous tuberculosis 
infection. 
 
Patient clinical, immunologic and demographic information were obtained from 
patient files, and results of blood samples, urine samples and kidney biopsies. The 
data were collected by a physician, Dr Wesley van Hougenhouck-Tulleken at CHBAH 
as part of his Masters of medicine research project.  
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Clinical and immunologic features, relevant to this study, that were documented were 
the following: 
 
SLICC Score 
The SLICC criteria are a list of criteria used in the diagnosis of SLE. SLICC criteria 
can be divided into those that are clinical or immunologic criteria. Clinical criteria 
include acute cutaneous lupus, chronic cutaneous lupus, oral or nasal ulcers, non-
scarring alopecia, arthritis, serositis, renal involvement, neurologic involvement, 
hemolytic anaemia, leukopenia and thrombocytopenia. Immunologic criteria include 
antinuclear antibodies (ANA), anti-dsDNA antibodies, anti-Sm antibodies, 
antiphospholipid antibodies, low complement C3, C4 and CH50 levels and the direct 
Coombs’ Test. Four SLICC criteria in a patient are required for making a diagnosis of 
SLE including at least one clinical and one immunological criterion (Bertsias et al., 
2012). 
 
Lupus Nephritis 
Certain tests were performed, such as the urine to protein creatinine (UPCR) test, to 
determine renal function. This test gives the protein to creatinine ratio found in the 
urine. A result that is greater than 300g/mmol creatinine translates to proteinuria 
(high levels of protein in the urine) (Bertsias et al., 2012). 
 
If a nephritis was suspected, a kidney biopsy was performed. From this the type of 
lupus nephritis could be determined. There are five classes of lupus nephritis: class I 
relates to minimal mesangial lupus nephritis; class II to mesangial proliferative lupus 
nephritis; class III to focal nephritis; class IV to diffuse nephritis; and class V to 
membranous nephritis. Class III, IV and V are the most severe types of lupus 
nephritis. 
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Tuberculosis (TB) 
Previous TB infection was determined from the patient’s medical records. If the 
patient had had TB previously the date of diagnosis and site (pulmonary and 
extrapulmonary) was noted. 
 
Complement C3 and C4 Levels 
C3 and C4 serum levels are determined via stimulation by a substance to produce an 
antibody using a turbidimetric technique. This technique measures the loss of light 
intensity passing through the solution based on its cloudiness. Low levels are 
considered below C3 0.2 and C4 -1.0 (Bertsias et al., 2012). 
 
Anti-dsDNA and Anti-Sm Antibodies 
Enzyme-linked immunosorbent assays (ELISA) are performed on blood samples to 
detect autoantibodies. Patients with anti-dsDNA antibody levels greater than 75 IU/ml 
and anti-Sm antibody levels greater or equal to 1 IU/ml together have a higher 
probability of having SLE, however, a negative anti-dsDNA antibody results does not 
exclude the diagnosis of SLE  (Bertsias et al., 2012) 
 
 2.3. Laboratory Methods 
2.3.1. Collection of Samples 
Blood samples were collected from each patient and control at the Chris Hani 
Baragwanath Academic Hospital by a trained research nurse. The blood samples 
were collected and stored in EDTA blood collection tubes to avoid coagulation of the 
blood and kept at -40C. 
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2.3.2. DNA Extraction 
Two EDTA tubes of blood were taken from each individual as this material and 
amount is optimal for DNA extraction. The blood samples were then frozen prior to 
extraction. The DNA was extracted using the Salting-Out method that was first 
described by (Miller et al., 1988). Approximately 10ml of blood is poured into a 
centrifuge tube and centrifuged for 10 minutes and the supernatant containing the 
plasma removed, the tube is then filled with a Sucrose-Triton X Lysing buffer, which 
lyses the blood cells. After mixing, by inverting the tube several times, centrifuge for 
10 minutes at 2300rpm after which the supernatant is discarded and a red pellet 
remains. The pellet is then resuspended in 20ml Sucrose-Triton X Lysing buffer and 
placed on ice for 5 minutes and then centrifuged again for 5 minutes at 2300rpm. The 
supernatant is again discarded and 3ml T20E5 (which chalates the Mg2+ molecules 
needed for DNA activity), 200µl 10% SDS (denature proteins) and 500µl Proteinase 
K solution (digest the proteins) is added to the pellet. After 24 hour incubation at 42ºC 
1ml of saturated NaCl solution is added. The NaCl salts out the proteins and forms a 
concentration gradient. The tube is centrifuged for 30 minutes at 2300rpm after which 
the supernatant, which contains the DNA, should be poured into a clean tube. 2 
Volumes of absolute alcohol is used to precipitate the DNA which is then air dried. 
The extracted DNA is then re-suspended in 1x TE buffer and stored in the fridge. 
 
2.3.3. Primer Design 
A PCR based method was used to determine the NA1 and NA2 alleles within 
samples from the SLE patients and controls. Primers were previously designed by 
Hong et al.  (2005) and are shown in Table 2.1.  
The primers were ordered and purchased from Whitehead Scientific and 
manufactured by IDT (San Diego, United States of America).  
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2.3.4. Allotyping Studies (NA1 and NA2) 
Genotyping was performed on each case and control sample. Genomic DNA 
fragments were amplified via PCR using specific amounts of the above-mentioned 
primers and other PCR components to a total reaction volume of 20µl (Table 2.2).  
The Bio Rad T100 Thermal Cycler machine was used. Twenty eight cycles were 
performed consisting of 93C for 1 minute, 60 C for 1 minute and 72C for 1 minute 
and 30 seconds. Extension occurred for 10 minutes at 72C after which PCR was 
terminated. A 20µl PCR product was run on a 2% agarose gel stained with ethidium 
bromide and visualised using a UV illumination system (Geldoc, Vacutec).  
 
 
 
 
 
Gene Sequence (5’3’) Annealing 
temp (˚C) 
Product  
size (bp) 
NA1 (F) CTCAATGGTACAGGGTGCTC 57.5 118 
NA1 (R) GGCCTGGCTTGAGATGAGGT 
NA2 (F) CTCAATGGTACAGCGTGCTT 57.8 171 
NA2 (R) CACCTGTACTCTCCACTGTGTCGTT 
GAPDH (F) CTCCTTTTGCAGACCACAGTCC 57.5 350 
GAPDH (R) CTGTTGAAGTCAGAGGAGACCAC 
Table 2.1: Primer sequences to amplify gDNA samples using PCR 
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2.3.5. Real-Time PCR 
All samples prior to real-time PCR were normalised to 20ng/µl using distilled water. 
This was confirmed using the NanoDrop spectrophotometry system whereby any 
read that was below 50ng/µl was considered acceptable. 
 
 
 
PCR Components Stock 
Concentration 
Final 
Concentration 
1X Mix (µl) 
DNA 
 
 2µl 
Kapa Taq Ready 
Mix 
  10µl 
NA1_F 10pmol/µl 5pmol 1.5µl 
NA1_R 10pmol/µl 5pmol 1.5µl 
NA2_F 10pmol/µl 5pmol 1.5µl 
NA2_R 10pmol/µl 5pmol 1.5µl 
GAPDH_F 10pmol/µl 5pmol 0.5µl 
GAPDH_R 10pmol/µl 5pmol 0.5µl 
ddH20   1µl 
Total   20µl 
Table 2.2: Standard PCR protocol for NA1 and NA2 allele determination  
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2.3.6. SNP Genotyping Assays 
SNP genotyping of the two FCGRIIIA gene SNPs rs10127939 and rs396991 were 
carried out using pre-designed TaqMan assays (Life Technologies) whereby allelic 
discrimination was used to determine the SNPs utilising allele specific probe 
chemistry. 
 
The SNP genotyping assays have been designed to detect single nucleotide 
polymorphisms (SNPs) within a genome. The specific TaqMan probes have a minor 
groove binder (MGB) on the 3’ part of the probe which binds to the minor groove of 
the DNA. The 5’ part of the probe contains a dye label such as VIC or FAM and on 
the 3’ side of the probe there is a quencher which quenches any fluorescence. There 
are two probes within the reaction. The first will be specific to a certain SNP and the 
other specific to another SNP. Each probe will contain a specific dye of different 
colours. Once the probe has bound and has been fragmented by the polymerase the 
specific colour fluorescence produced directly correlates to the SNP present (Thermo 
Fisher, 2013) 
 
The SNP genotyping assays were received at a concentration of 40X and were 
stored at -20C in dark conditions. This assay was diluted down to a concentration of 
20X using 1 X TE buffer as per manufacturer instructions. Aliquots of the 20X 
working stock were prepared. The PCR reaction setup involved preparing the 
reaction mix and the reaction plate. The reaction mix consisted of 2.5µl TaqMan 
Genotyping Master Mix and 0.25µl of 20X TaqMan genotyping assay. The reaction 
mix calculations were adjusted in order for there to be sufficient volume for each well 
of a 384-well plate. Each well was required to have 2.75µl of reaction mix. Once the 
reaction mix was complete, 2.75µl of reaction mix were added to each well of the 
reaction plate. DNA from each case and control (2.25µl) were added to the separate 
wells. Therefore each well of the reaction plate had a final volume of 5µl. 
 
The plate was covered in an adhesive film and centrifuged briefly. The reaction plate 
included samples of known genotype, samples of unknown genotype and two no 
33 
 
template controls (distilled water). Samples of known genotype were determined via 
sequencing whereby 10 samples were randomly chosen to be genotyped. 
 
The plate document was set up and labelled and then PCR was performed using the 
7900HT Fast System real-time PCR system. PCR conditions were as follows: 95C 
for 10 minutes once only, 95C for 15 seconds and 60C for 1 minute for a total of 40 
cycles. Thereafter, PCR was terminated, the plate was removed and the alleles were 
determined via fluorescence measurements made during the plate read. Software 
was then used for interpretation of results. This was done for both SNPs that were 
required to be genotyped in this study.  
 
 2.3.7. Reproducibility 
Assay reproducibility was performed for the genotypes obtained during the TaqMan 
assays to determine the reliability of the assays. 30 SLE samples (20%) were re-run 
using the same TaqMan assays previously used. Samples were chosen at random 
but included all genotypes previously called. 
 
2.3.8. Copy Number Variation (CNV) Assay 
A TaqMan copy number assay specific to the FCGRIIIB gene was used to determine 
copy number variation. The TaqMan copy number assay uses relative quantification 
whereby the reference assay detects a sequence that is known to be present in two 
copies in the diploid genome. The RNase P reference assay was used. This assay 
detects the Ribonuclease P RNA component H1 (H1RNA) gene (RPPH1) on 
chromosome 14.  
 
The CNV assays were received at a concentration of 20X and were stored at -20C 
in dark conditions. Aliquots of the 20X working stock were prepared. The PCR 
reaction setup involved preparing the reaction mix and the reaction plate. The 
reaction mix consisted of 5µl TaqMan Gene Expression Master Mix, 0.5µl of 20X 
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TaqMan CNV assay and 0.5µl of TaqMan Copy Number Reference Assay. The 
reaction mix calculations were adjusted in order for there to be sufficient volume for 
each well of a 384-well plate. Each well was required to have 8µl of reaction mix. 
Once the reaction mix was complete, 8µl of reaction mix were added to each well of 
the reaction plate. DNA from each case and control (2µl) were added to the separate 
wells. Therefore each well of the reaction plate had a final volume of 10µl. 
 
The plate was covered in an adhesive film and centrifuged briefly. The reaction plate 
included samples of unknown copy number, a sample of known copy number 
(calibrator sample) and two no template controls (distilled water).  
 
The plate document was set up and labelled and then PCR was performed using the 
Applied Biosystems 7900HT Fast System real-time PCR system. PCR conditions 
were as follows: 95C for 10 minutes once only, 95C for 15 seconds and 60C for 60 
seconds for a total of 40 cycles. Thereafter, PCR was terminated, the plate was 
removed and the copy numbers of each sample were determined. Software was then 
used for interpretation of results. 
 
2.3.9. Analysis of Real-Time PCR 
The genotyping and copy number assay results were analysed using their 
corresponding analysis softwares. TaqMan Genotyper, for the SNP genotyping 
assays and Copy Caller, for the CNV analysis. These are free for download from the 
Life Technologies website.  
 
2.4.    Statistical Analyses 
Pearson’s chi-squared (χ2) test was used to determine whether proportions of 
genotypes were consistent with Hardy-Weinberg Equilibrium using a significance 
threshold of p<0.05. The chi-squared (χ2) test determines the amount of deviation 
between the observed genotype frequencies and those expected under HWE. 
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Genotype and allele frequencies were calculated for all cases and controls, these 
allele frequencies were compared using Pearson’s chi-squared (χ2) test with a 
statistical significance level threshold of p<0.05, to test for association with SLE. In 
addition, lupus nephritis cases underwent further statistical analyses. 
 
Two sample t-test was used to compare percentages obtained from the copy number 
studies. Standard statistical software such as stata or graphpad prism was used. 
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Chapter 3 
 
Results 
3.1.     Patient Demographics and Clinical Variables 
The majority of patients were females (93.8%). The mean disease duration was 6.7 
years. Lupus nephritis (LN) severity was graded into categories by a nephrologist. 
The majority of the patients biopsied had LN class III and class V. Approximately a 
quarter of patents had a history of TB. Two thirds of the patients had low complement 
levels. The demographic, clinical and laboratory data for the patient group are 
summarised in Table 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Feature Patients (n= 162) 
Female: Male ratio 13.5 : 1 
Age of patient in years- mean (SD) 39.1 (12.4) 
Age of disease onset in years- mean (SD) 32.4 (15.3) 
SLICC Score- mean (SD) 8 (2.2) 
Lupus nephritis 43.8% (n=71) 
Lupus nephritis Class I 2.5% (n=4) 
Lupus nephritis Class II 4.3% (n=7) 
Lupus nephritis Class III 12.3% (n=20) 
Lupus nephritis Class IV 4.9% (n=8) 
Lupus nephritis Class V 19.8% (n=32) 
Previous TB infection 23.5% (n=38) 
Low C3 and C4 levels 66.7% (n=108) 
Anti-dsDNA Antibodies 42% (n=68) 
Anti-Sm Antibodies 72.8% (n=118) 
Table 3.1: Mean values for the demographic, clinical and laboratory data for the SLE 
patients  
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3.2.    Allotype Studies 
Figure 3.1 represents the allelic and genotypic frequencies of the NA1 and NA2 
alleles in SLE patients and controls. The 118bp PCR product represented the NA1 
allele and the 171bp PCR product represented the NA2 allele (Figure 3.2). The 
genotype frequencies in controls (χ²= 0.87; p = 0.3438) were found to be in 
agreement with HWE expectations. Conversely, the genotype frequencies in SLE 
patients (χ²= 11.75; p = 0.0006) were not in agreement with HWE expectations.  
 
NA1 and NA2 allelic association in SLE is shown in Table 3.2. The minor allele NA2 
does not confer susceptibility to SLE (OR = 1.281, 95% CI: 0.902-1.817, p =0.166), 
with a minor allele frequency of 31% in cases and 37% in controls. The NA2 allotype 
exceeded the threshold p<0.05 and therefore is not statistically significant in 
conferring susceptibility to SLE in Black South Africans. 
a. 
b. 
Figure 3.1: Pie charts illustrating the observed genotypes (a) and allele frequencies (b) of NA1 and 
NA2 
 
Genotype frequencies and allele frequencies in 141 cases and 155 controls. 
 
63% 
37% 
Controls 
NA1
NA2
49% 
15% 
28% 
8% 
Cases 
NA1/NA1
NA2/NA2
NA1/NA2
Null Allele
38% 
12% 
49.5% 
0.5% 
Controls 
NA1/NA1
NA2/NA2
69% 
31% 
Cases 
NA1
NA2
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Table 3.2: Statistical analysis of results from the NA1 and NA2 alleles 
 
  
3.3    SNP Genotyping 
 
3.3.1. rs10127939 
 
All SLE cases and controls were analysed using the TaqMan assay designed 
specifically for the tri allelic SNP rs10127939. Firstly an assay to detect the presence 
of the T and A allele was run. No amplification was seen for the A allele in both cases 
and controls (Figure 3.3c). Only the T allele showed amplification (Figure 3.3b). 
Secondly, an assay to detect the presence of the T and G allele in the same samples 
Major allele Minor allele Case 
MAF 
Control 
MAF 
OR 
(95% CI) 
Chi-square 
value 
P-value 
NA1 NA2 
0.31 0.37 
1.281 
(0.902-1.817) 
1.92 0.166 
Figure 3.2: PCR amplification via agarose gel electrophoresis of allotypes NA1 and NA2 
 
 
Lane 1: 1kb molecular weight marker; lanes 2- 6: SLE cases; lanes 7- 11: controls; lane 12: blank 
NA1 can be seen as a product of 118bp, NA2 of 171bp and the internal control, GAPDH, at 350bp. 
  
  
  
 1       2        3        4        5        6       7        8         9        10      11     12 
118bp NA1  
171bp NA2  
350bp GAPDH  
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was run. This assay again showed no amplification of the G allele and only the T 
allele amplified in both cases and controls. Validation of the genotyping confirmed the 
presence of only the T allele in these samples (Figure 3.3d). One can conclude that 
because neither the cases nor controls carried the A and G variants, that the A 
variant is monomorphic within the South African population. Therefore, the 
polymorphism does not confer susceptibility to SLE in the Black South African 
population. 
a. 
c. 
b. 
d. 
Figure 3.3: Amplification plot and allelic discrimination plot results of rs10127939 
  
(a) Amplification plot of both alleles. 
(b) Amplification plot of allele 1 showing amplification 
(c) Amplification plot of allele 2 showing no amplification 
(d) Allelic discrimination plot showing only allele 1 is present in the samples run 
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3.3.2. rs396991 
 
Allelic discrimination for the G and T allele in SNP rs396991 was again performed 
using TaqMan technologies. Figure 3.4 shows an example of one of the allelic 
discrimination plots created whereby the three genotypes are plotted against the x 
and y-axes. Figure 3.5 represents the frequencies of the alleles and genotypes of the 
rs396991 SNP as calculated in the SLE patients and controls. The genotype 
frequencies in SLE cases (χ²= 0.2; p = 0.65) and controls (χ²= 0.11; p = 0.74) were 
both in agreement with HWE expectations.  
 
T and G allelic association in SLE is shown in Table 3.3. The minor G allele does not 
confer susceptibility to SLE (OR = 1.135, 95% CI: 0.811-1.588, p =0.654), with a 
minor allele frequency of 32% in cases and 35% in controls. This G allele exceeded 
the threshold p<0.05 and therefore is not statistically significant in conferring 
susceptibility to SLE in Black South Africans. 
Figure 3.4: Allelic discrimination plot of selected SLE samples and controls for rs396991 
  
Red dots denote individuals with TT genotypes, green dots with TG genotypes and blue dots with GG 
genotypes. The no template controls (NTC) can be seen as two black squares. Samples that could not be 
determined can be seen as black crosses. The different genotypes cluster together along the x and y-axes. 
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Table 3.3: Statistical analysis of results from rs396991 
 
 
 
Major allele Minor allele Case 
MAF 
Control 
MAF 
OR 
(95% CI) 
Chi-square 
value 
P-
value 
T G 
0.32 0.35 
1.135 
(0.811-1.588) 
0.85 0.654 
Figure 3.5: Pie charts illustrating the observed genotypes (a) and allele frequencies (b) of 
rs396991 
  
Genotype frequencies and allele frequencies in 152 cases and 154 controls. 
  
a. . 
b. 
11% 
42% 
47% 
Cases 
TT
TG
GG
12% 
47% 
41% 
Controls 
TT
TG
GG
68% 
32% 
Cases 
T
G
65% 
35% 
Controls 
T
G
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3.4.    Lupus Nephritis 
 
Lupus nephritis (LN) was present in 43.8% (n=71) of cases. Majority had the severe 
forms of nephritis III, IV and V (84%). The allele frequencies of the allotypes and the 
SNP rs396991 were calculated for LN cases and non-LN cases (Figure 3.6). The 
allele frequency of NA1 in LN cases was 0.73 and NA2 was 0.27, whereas the allele 
frequency in non-LN cases was NA1 at 0.59 and NA2 at 0.41. The FCGRIIIB 
NA1/NA2 does confer susceptibility to LN (OR = 1.879, 95% CI: 1.109-3.184, X2= 
5.57, p =0.018).  
 
The allele frequency of T in LN cases was 0.31 and G was 0.69, whereas the T allele 
frequency in non-LN cases was 0.28 and G at 0.72. The minor allele G does not 
confer susceptibility to LN (OR = 1.121, 95% CI: 0.693-1.813, X2= 0.215, p =0.643), 
with a minor allele frequency of 69% in cases and 72% in controls.  
 
Of the LN cases, 22.4% had null-alleles whereas 7.37% of non-LN cases had null-
alleles. Null alleles in this study refers to the absence of the FCGRIIIB gene. This can 
indicate that low or no copy number of FCGRIIIB is associated with lupus nephritis, 
as seen in other population groups (Niederer et al., 2010). A two-sample t-test was 
performed between the percentages of null-allele individuals at an alpha level of 0.05 
and degrees of freedom of 160. The t-statistic calculated was 2.75 and the p-value 
was 0.007. 
 
The mean copy number of FCGRIIIB was calculated for LN cases and was found to 
be 1.995. This is below 2 copies and is consistent with previous studies that a copy 
number of ≤2 confers susceptibility to LN. 
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a. 
b. 
Figure 3.6: Pie charts illustrating the allele frequencies of NA1/NA2 allotypes in LN and non-LN 
cases (a) and allele frequencies of rs396991 in LN and non-LN cases 
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3.5.    Copy Number Variation 
 
Copy numbers of cases and controls were calculated using the CopyCaller software 
(Figure 3.7). Each sample was analysed in duplicate with the average of these two 
values used to calculate the percentage of copy numbers (Figure 3.8a). Copy 
numbers were categorized as either 0, 1, 2, 3 or 4 copies.  The cumulative 
percentages of ≤2 copies and >2 copies were then calculated for cases and controls 
as this was the focus of the study (Figure 3.8b). 
 
A two sample t-test between percents was performed to see if there was a significant 
difference between ≤2 copies and >2 copies seen in cases and controls (Quirks Stats 
Calculator). At an alpha level of 0.05 and degrees of freedom of 307, the t-statistic 
was 0.219 and the p-value was 0.826. Due to the p-value being greater than 0.05, 
the difference is not significant.  
Figure 3.7: Bar graph representing copy number variation found in the FCGRIIIB gene in SLE 
cases and controls 
  
Each line on the x-axis represents a sample that was run. The lines are colour coded into green, 
purple and blue to represent the three different plates run as all samples could not fit onto one plate. 
The y-axis represents the number of copy numbers and is numbered from 0 copies to 5 copies. 
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b. 
a. 
Figure 3.8: Pie charts illustrating the observed copy numbers of FCGRIIIB in cases and 
controls 
  
(a) Copy number variation categorised as 0- 4 copies  in 154 cases and 155 controls 
(b) Copy number variation categorised as ≤ 2 copies and > 2 copies in 154 cases and 155 controls 
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40.30% 
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1.95% 
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0 copies
1 copies
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4 copies
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Chapter 4 
Discussion 
4.1. Clinical Variables 
Analysis of clinical variables revealed that the majority of the SLE patients were 
female (93.8%). The mean age of the patient at diagnosis was 32.4 years and the 
mean current age of the patients was 39.1 years. This translates to the mean disease 
duration being 6.7 years. The SLICC criteria further make diagnosis more accurate. 
There are 17 criteria whereby four must be present to make a positive diagnosis (Yu 
et al., 2014, Bertsias et al., 2012). In this study, the mean SLICC score was eight. 
Lupus nephritis was present in 43.8% of patients and this percentage was broken 
down into the five classes of lupus nephritis. 23.5% of patients were recorded to have 
previous TB infection. Immunologic factors were investigated such as low levels of 
complement 3 and 4 proteins (66.7%), presence of anti-ds DNA antibodies (42%) 
and presence of anti-Sm antibodies (72.8%). 
 
The female to male ratio in this study was 13.5 females to 1 male. This correlates to 
numerous previous studies of 9 females to 1 male ratio (Elkon and Santer, 2012). A 
previous South African study performed at the same location as this study, Chris 
Hani Baragwanath Academic Hospital, also had this female to male ratio (Benitha 
and Tikly, 2007). The fact that the female ratio is slightly higher, than seen in 
populations in this study, may be due to gender bias whereby certain restrictions 
according to age, ethnicity and SLICC criteria excluded more male patients present 
at the clinic. 
 
The mean age of patients at diagnosis was 32.4 years. In previous studies this mean 
age was 31.5 years (Benitha and Tikly, 2007, Mody et al., 1994, Wadee et al., 2007). 
Benitha and Tikly (2007) presented evidence that 84% of patients are diagnosed with 
SLE before 40 years of age. The data in this study agree with this statement. The 
mean age of patients when recruited for this study was 39.1 years. This is only 
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slightly higher than previous studies performed at Chris Hani Baragwanath Academic 
Hospital in Johannesburg and King Edward VIII Hospital and Inkosi Albert Luthuli 
Hospital in Durban, whereby the current mean age at recruitment was 36 years 
(Benith and Tikly, 2007, Patel and Mody, 2013).  
 
Disease duration is considered from the date of diagnosis. The mean length of 
disease duration was 6.7 years. Studies conducted in hospitals in Johannesburg and 
Durban, South Africa showed the mean disease duration to be 4.5 years (Benitha 
and Tikly, 2007, Dubula and Mody, 2015). The 2.2 year discrepancy could be 
attributed to delayed diagnosis or patients who do not and cannot afford to seek help. 
27.1% of South Africans are unemployed and these people cannot afford transport to 
travel to state hospitals (Stats SA, 2016). People who are employed are often not 
able to take off work to visit state hospitals on the designated clinic days.  
 
People with African ancestry with SLE often exhibit a more aggressive disease (Tikly 
et al., 1996, Wadee et al., 2007). This involves more renal involvement and infection. 
The mean SLICC criteria in this study, which are criteria involved in SLE diagnosis, 
was eight. This translates to 67% of criteria being met in this patient cohort. Criteria 
involve clinical and immunologic aspects. This study examined three immunologic 
criteria, these being: anti-ds DNA antibodies, anti-Sm antibodies and low complement 
levels. These three criteria are specific to autoimmune diseases and are important in 
the positive diagnosis of SLE (Bertsias et al., 2012).  
 
42% of patients in this study had anti-ds DNA antibodies and 72.8% of patients had 
anti-Sm antibodies present. Tikly et al.  (1996) identified the autoantibodies present in 
Black South African patients. Ro antibodies were seen in 60.5% of patients, La 
antibodies in 28.4%, Sm antibodies in 44.2% and anti-ds DNA antibodies at 40.8%. 
Anti-Sm and anti-RNP antibodies are the most commonly seen autoantibodies in 
Black patients (Mody et al., 1994). In this study a far greater percentage of patients 
had anti-Sm antibodies than seen in previous studies. This could be attributed to 
better testing methods and diagnosis. Anti-ds DNA antibodies in this cohort correlate 
to what has been previously seen. 
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A low complement level of C3 and C4 indicate a defective complement pathway and 
autoimmune diseases such as SLE. In this study 66.7% of patients had low 
complement levels. However, no published South African data exist regarding 
previous studies on complement levels. Therefore one cannot compare the values 
obtained in this study to previous values. 
 
Lupus nephritis (LN) and infection are major contributors to mortality in Black South 
African SLE patients (Dubula and Mody, 2015, Mody et al., 1994, Patel and Mody, 
2013). Lupus nephritis, once diagnosed, can be categorised into five grades. Grade I 
is considered the least severe while grade V is considered the most severe. In this 
study 43.8% of patients had LN. This accounts to just under half of the cohort having 
LN and emphasises the importance of diagnosing and treating LN in South Africa.  
 
Of the 43.8%, 2.5% had grade I LN, 4.3% had grade II, 12.3% had grade III, 4.9% 
had grade IV and 19.8% had grade V. The majority of LN patients had grade III and 
grade V, the higher level grades of LN. This correlates to previous data whereby LN 
is a main cause for mortality in SLE. Previous studies have shown that grade III and 
grade V LN is increasing whereas grade II is decreasing. This trend is seen in these 
data whereby the majority of patients were grade III (12.3%) and grade V (19.8%). 
Grade II was seen at a lower frequency of 4.3%. 
 
Lupus nephritis affects renal function whereby antigen-antibody complexes 
accumulate in the kidneys causing glomerulonephritis (Brown et al., 2007, Karassa et 
al., 2003, Kyogoku et al., 2004). This results in kidney damage and loss of filter 
function. The fact that people of African ancestry tend to experience a more severe 
disease agrees with the high rate of LN present in Black SLE patients in South Africa. 
The allele frequencies and copy number variation were investigated in LN and non-
LN cases and will be discussed in the respective sections. 
 
Another consequence of SLE is infection. Infection susceptibility increases if the 
immune system is compromised due to autoantibody status, disease duration and 
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immunosuppressive medication use (Cervera et al., 2003). SLE patients have higher 
infection rates than seen in the healthy population (Dubula and Mody, 2015). 
Infections such as TB, pneumonia, sepsis and urinary tract infections (UTIs) 
contribute to SLE patient mortality. TB infection can be divided into pulmonary and 
extra-pulmonary TB although this study did not take this into account. Previous TB 
infection was present in this study cohort at 23.5%. This is a large percentage when 
taking into account that other infections were not documented. Therefore, one can 
conclude that there is a link between SLE and infections such as TB. In previous 
studies TB was seen in 20% of patients. However, taking into account the other 
infections, this number rose to 35.2% (Dubula and Mody, 2015). 
 
From this study, one can see that the majority of South African SLE patients are 
female. The disease status is also more aggressive by the mean amount of SLICC 
criteria present as well as the immunologic statistics. Lupus nephritis and TB infection 
is prevalent in Black South African patients translating to poor disease prognosis. 
 
4.2.    Allotype Studies 
The allotypes or allelic variants investigated in this study were NA1 and NA2 which 
are present on neutrophils and are encoded by the FCGRIIIB gene. The NA2 allele is 
associated with reduced binding efficiency of antigen-antibody complexes, whereas 
the NA1 allele has a higher binding capacity (Gessner et al., 1998, Hatta et al., 1999, 
Lehrnbecher et al., 2000, Morris et al., 2010, Tanaka et al., 2005). Some studies 
have shown the NA1 allele to be overrepresented in healthy Black South Africans 
(Lassauniere and Tiemessen, 2016). However, studies on other African populations 
show the NA1 allele to be underrepresented (Hessner et al., 1996, Hessner et al., 
1998, Kissel et al., 2000, Lehrnbecher et al., 1999, Matsuo et al., 2000, Moritz et al., 
2008). 
 
After genotyping using target-specific PCR primers, the genotype and allele 
frequencies were calculated. The allele frequencies of the cases were NA1 at 0.69 
and NA2 at 0.31 and the controls were NA1 at 0.63 and NA2 at 0.37. The genotype 
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frequencies of the cases and controls were tested using Pearson’s chi-squared (χ2) 
test to determine whether proportions of genotypes are consistent with Hardy-
Weinberg Equilibrium using a significance threshold of p<0.05. It was found that 
controls (X2=0.87; p=0.3438) were in agreement with HWE whereas cases 
(X2=11.75; p=0.0006) were not. This is most likely due to sample bias whereby the 
cases are enriched for a certain trait (Salanti and Ioannidis, 2008). 
 
The allele frequencies calculated were compared using Pearson’s chi-squared (χ2) 
test, to test for association with SLE. The minor allele frequencies (MAF) were 
compared. An odds ratio of 1.281 was calculated at a 95% confidence interval 
(0.902; 1.817).  The p value of 0.166 exceeded the threshold of p<0.05 and therefore 
the NA2 allele is not statistically significant in conferring susceptibility to SLE. 
However, the odds ratio value is >1 which translates to this allele being associated 
with SLE. The fact that the p value is >0.05 means that the probability that this allele 
is associated with SLE is more due to chance than it actually being associated with 
the disease (Gianfrancesco et al., 2016). If the p value were to be <0.05 and the 
OR>1 one could state that the NA2 allele is associated with SLE in Black South 
Africans. 
 
It is interesting to note that there was a frequency of 0.08 of NA-null genotypes in 
cases and a frequency of 0.005 of NA-null genotypes in controls. These figures were 
however, not included in the data analysis. There is a higher frequency of NA-null in 
cases which means that these patients are deficient in the FCGRIIIB gene. Having no 
NA allele may confer susceptibility to SLE, although this was not statistically 
determined in this study due to the low numbers of patients. However, this idea 
corresponds to the low copy number of FCGRIIIB in cases that have been seen in 
previous SLE studies. 
 
In LN cases the allele frequency of NA1 is 0.73 and NA2 is 0.27. In the literature, the 
low binding NA2 allele is said to be associated with SLE and LN (Gessner et al., 
1998, Hatta et al., 1999, Lehrnbecher et al., 2000, Morris et al., 2010, Tanaka et al., 
2005). After statistical analysis, NA1/NA2 was shown to confer susceptibility to LN in 
51 
 
this study and this cohort (Lee et al., 2009). Non-LN cases had an NA1 allele 
frequency of 0.59 and NA2 of 0.41.  
 
4.3.    SNP Genotyping 
4.3.1. rs10127939 
The rs10127939 SNP is a tri-allelic SNP that results in either a thymine to adenine or 
guanine base change at position 230 (c. 230T>G>A). This base change will also 
result in an amino acid change at position 48 (p. L48R/H). Previous studies have 
shown that being homozygous for the A allele results in severe immunodeficiency 
and high infection rates (de Vries et al., 1996). This is important as this study looks at 
SLE, an autoimmune disease and infections are commonly seen in Black South 
African SLE patients. Therefore this SNP was hypothesised to confer susceptibility to 
SLE in this population. 
 
The allele frequencies in Caucasian control studies have found T at 0.86, G at 0.06 
and A at 0.08 (de Haas et al., 1996, de Vries et al., 1996). The Yoruba of Nigeria 
studied in the HapMap project have the T allele at a frequency of 0.91, G at 0.09 and 
the A at 0.00. To date there is no data available of the genotype frequencies of this 
SNP in Black South Africans. 
 
In both Caucasians and the Yoruba, the T allele is present at a very high frequency 
and the G allele is seen at a low frequency. The A allele is also present at a very low 
frequency and is not seen at all in the Yoruba. This strongly suggests that the A allele 
may also not be present in the Black South African SLE patients or controls. 
 
Upon investigation, whereby all three alleles were genotyped for, the G and A allele 
were not present in either cases or controls. All cases and controls were genotyped 
to be homozygous for the T allele. Previous studies have described and confirmed 
this whereby this SNP is not polymorphic in Black South Africans (Lassauniere et al., 
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2013; Lassauniere and Tiemessen, 2016). Therefore, the rs10127939 SNP is non-
polymorphic or monomorphic in Black South Africans, as was seen in a similar study 
for a different SNP (Tikly et al., 2010). As both cases and controls are monomorphic 
for the T allele, one can conclude that this SNP confers no susceptibility to SLE in 
Black South Africans. Perhaps a bigger sample size could completely prove that the 
G and A allele are not present within Black South Africans. 
 
4.3.2. rs396991 
The rs396991 single nucleotide polymorphism results in a thymine to guanine base 
change at position 559 (c. 559T>G). This will also result in an amino acid change at 
position 176 (p. F176V). The T allele results in reduced binding capacity of the 
receptor to clear immune complexes thus resulting in increased inflammation (Deng 
and Tsao, 2010, Li et al., 2009, Sestak et al., 2011, Tanaka et al., 2005). 
 
Previous studies have shown the T allele confers a 1.2 fold risk increase for 
developing lupus nephritis in Europeans, Africans and Asians (AlFadhli, 2012, 
Alizadeh et al., 2007, Brown et al., 2007, Karassa et al., 2003, Kyogoku et al., 2004, 
Sestak et al., 2007). This study aims to determine if this SNP confers susceptibility to 
SLE in Black South Africans. 
 
The allele frequencies in Black South African controls have found the T allele at 0.63 
and the G allele at 0.37 (Lassauniere and Tiemessen, 2016). Other studies using 
Caucasian controls have found the T allele at 0.74 and the G allele at 0.26 (Koene et 
al., 1998, Lehrnbecher et al., 1999). The Yoruba of Nigeria studied in the HapMap 
project see the T allele is found at 0.96 and the G allele at 0.04. As with the previous 
SNP one can see that the allele frequencies of the Yoruba and Black South Africans 
are not comparable and are in fact very different. 
 
In this study, the allele frequencies of the cases were T at 0.68 and G at 0.32 and the 
controls were T at 0.65 and G at 0.35. This sample and these values underwent 
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statistical analysis. The genotype frequencies of the cases and controls were tested 
using Pearson’s chi-squared (χ2) test to determine whether proportions of genotypes 
are consistent with Hardy-Weinberg Equilibrium using a significance threshold of 
p<0.05. It was found that both cases (X2=0.2; p=0.65) and controls (X2=0.11; p=0.74) 
were in HWE. Controls should always be in HWE as they should represent the 
greater population. There are however ongoing debates as to whether cases, which 
are enriched with a certain trait, should or should not be present in HWE (Salanti and 
Ioannidis, 2008).  
 
The allele frequencies calculated were compared using Pearson’s chi-squared (χ2) 
test, to test for association with SLE. The minor allele frequencies (MAF) were 
compared. An odds ratio of 1.135 was calculated at a 95% confidence interval 
(0.811; 1.588). The p value of 0.654 exceeded the threshold of p<0.05 and therefore 
the G allele is not statistically significant is conferring susceptibility to SLE 
 
However, even though this SNP is not statistically significant, one can still see that 
the low-binding T allele was seen in cases at a 0.03 higher frequency than in 
controls. This may translate to an association in future studies. Perhaps a bigger 
sample size would be required to be able to see such an association. 
 
The allele frequencies were calculated in LN and non-LN cases. In LN cases the T 
allele was seen at 0.31 and the G allele at 0.69. In non-LN cases the T allele was 
seen at 0.28 and G allele at 0.72. There was no large difference between allele 
frequencies in both groups and after statistical analysis it was seen that the minor 
allele, G, does not confer susceptibility to LN. This SNP therefore does not act as risk 
factor for developing LN in Black South African SLE patients. 
 
4.4.   Copy Number Variation 
A low copy number and therefore a deficiency in the FCGRIIIB gene has been linked 
to systemic autoimmunity (Fanciulli et al., 2007). In a study performed by Morris et al.  
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(2010) on Caucasian SLE patients showed the mean copy number in cases to be 
1.981 copies and in controls to be 2.052 copies. This trend has been seen in studies 
of different population groups. 
 
Lassauniere and Tiemessen (2016) found that healthy Black individuals were found 
to have one gene copy of FCGRIIIB at 7.6%, two gene copies at 74%, three gene 
copies at 15.3% and four gene copies at 3.1%. Therefore, 81.6% of these healthy 
individuals have ≤2 copies. However, these values were not compared to SLE cases. 
In the present study, 5.84% of cases had 0 copies, 40.3% had 1 copy, 48.01% had 2 
copies, 3.9% had 3 copies and 1.95% had 4 copies. The cumulative percentages of 
copies ≤2 was 94.15% and copies >2 was 5.85%. In the controls, 5.8% of controls 
had 0 copies, 54.2% had 1 copy, 33.55% had 2 copies, 5.8% had 3 copies and 
0.65% had 4 copies. The cumulative percentages of copies ≤2 was 93.55% and 
copies >2 was 6.45%.  
 
This study shows that 54.1% of controls have one copy, whereas only 7.6% of 
healthy Black South Africans in the Lassauniere and Tiemessen (2015) study have 
one copy. This large discrepancy highlights the inaccuracy in which this data was 
generated. The level of accuracy of the assays and method of data interpretation 
may have been a factor in assigning different copy numbers. In fact, other ways in 
which to interpret the data is not to calculate the mean of copy numbers but to take 
the relative values as a continuum. It is recommended in future studies that multiplex 
ligation probe assays (MLPA) should be used, instead of the TaqMan assay. MLPA is 
more accurate and would be more effective in giving confident results. 
 
It is interesting to note that the SLE cases had almost 2% of individuals having 4 
copies. Previous studies have shown that having more copies of FCGRIIIB acts as a 
protective effect against developing LN and SLE but in this study this was not seen. 
Both cases and controls had approximately 5.8% of individuals who had 0 copies yet 
the controls did not have SLE. This could mean that having no copy of FCGRIIIB 
cannot always translate to developing an autoimmune disorder or perhaps those 
control individuals will develop symptoms over a period of time. Once the copy 
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number was cumulatively calculated, one can see that SLE cases had a larger 
number of individuals who have ≤2 copies. This corresponds to what is seen in the 
literature as having fewer copies results in SLE.  
 
A two-sample t-test was performed between the cumulative percentages at an alpha 
level 0f 0.05 and degrees of freedom of 307. The t-statistic calculated was 0.219 and 
the p-value was 0.826. The p-value is greater than 0.05 and therefore there is no 
significant difference between percentages in cases and controls. Although this 
cannot be proven statistically, the trend that SLE cases had more individuals with 
lower copy numbers shows that in this cohort, low copy number is still a risk in 
developing SLE. Therefore, even if not significant, there is still a 0.6% increase of ≤2 
copies seen in cases compared to controls. This correlates to what is seen in the 
literature. 
 
Copy number variation was calculated in lupus nephritis (LN) and non-LN cases to 
see if this type of variation could be a risk factor in developing LN. 43.8% of cases 
had LN and the mean copy number within these individuals was 1.995 copies. Copy 
number of ≤2 has been linked to SLE and kidney disease and therefore one can 
suggest that a lower copy number can increase the risk of developing LN. Previous 
studies on rats have shown that a low copy number has been associated with 
glomerulonephritis in SLE (Aitman et al., 2006). Non-LN cases (56.2%) had a mean 
copy number of 2.102 copies. This number is above 2 copies and therefore suggests 
that a higher copy number lowers the risk of developing LN. In fact, having ≥2 copies 
has a protective effect against developing LN (McKinney and Merriman, 2012, Tiffin 
et al., 2013). Although the differences of copy number in LN cases and non-LN cases 
is not very large, there is still obvious dissimilarity that should not be overlooked. 
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4.5.    Strengths and Weaknesses of Study 
The strengths of this study include the amount of clinical data obtained at the time of 
the blood extraction. Many clinical and immunological variables, including lupus 
nephritis, were included which added further value to this study. The genotyping 
method that was used for the two SNPs as well as the CNV study was TaqMan 
technology. This technology is known as the gold standard in quantitative genomics 
and confidently calls results. This eliminates the chance that human error could 
influence the results.  
 
Demographics of the controls were not available, except for the race of the controls. 
It would be preferable to match the cases and controls as closely as possible to 
gender ratio and age in order to have no variability within the sample. Some DNA 
samples that were extracted from the blood of patients were not of good quality. This 
affected the ability for them to be used in certain study methods and they had to be 
excluded. This impacted further on the sample size. The sample size was not very 
large and this could have affected some results. The power of the study is therefore 
not as strong as one would want. The allotype determination was performed using 
PCR. This may cause the results from the study to have some level of human error 
as the amplification products were interpreted manually. Genotyping reproducibility 
only tested 20% of the SLE cases. This percentage may be too low to confidently 
validate the data that were produced. These genotyping results should have been 
validated using another genotyping method or by running the assay in another 
laboratory. The SH allotype was not genotyped and certain studies have shown that 
the SH allotype would be assigned as NA2 allotypes, if not genotyped. This therefore 
has major potential to confound results making interpretation of the data dubious. 
The function of SH is not known in the literature and the genotyping of SH in the 
Black South African population would result in novel data. 
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4.6.   Significance of Study 
The present study integrates and analyses immunologic, clinical and genetic data. 
This is the first study to investigate these specific genetic polymorphisms in the South 
African population and the results aid in a better understanding of the genetic 
aetiology of SLE in black South African patients. Of particular interest were those 
SLE patients who developed Lupus nephritis (LN), as recurrent infections in these 
patients are a major cause of mortality. This study looked at the percentage of 
patients with LN and previous TB infection and concluded that these particular 
patients are at a greater risk of infection than those patients who do not develop LN. 
These data will allow clinicians to better treat LN patients thereby improving current 
treatment strategies. Therefore use of both comprehensive clinical data as well as 
genetic data enables a better understating of the disease pathogenesis and 
progression in this unique population as well as highlights the importance of a 
multidisciplinary approach to genetic and clinical research. Finally, the results from 
this study once again emphasise the uniqueness of our population and highlights the 
continued need for further studies to better understand the pathogenesis of disease 
in our population.   
 
4.7.      Further Research 
Firstly, the genotyping data obtained were from a relatively small sample size. 
Genotyping results should be reassessed by using a larger sample size of both cases 
and controls. This would increase the power of the study and would give more 
accurate results. The allotype studies should be considered being done using a more 
reliable genotyping method such as TaqMan genotyping assays instead of using 
agarose gel electrophoresis in which the interpretation may be inaccurate. In this 
study two SNPs were investigated. In future studies it would be beneficial to look at 
more SNPs within the FCGRIIIA and FCGRIIIB genes as this population is unique 
and data pertaining to these genes is scarce. In order to determine CNV, an MLPA kit 
should be used instead of Taqman assays as it is more accurate and allows for the 
detection of other FCGR variants (Lassauniere et al., 2013). 
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Secondly, one could investigate gene expression within these genes in addition to 
genotyping. Gene expression could use biomarkers in the diagnosis of patients. 
These biomarkers could be tested for and could be used in a more timeously 
diagnosis. One could investigate gene expression in other genes linked to SLE such 
as BANK1, ITGAM, PTPN22, STAT4 and PDCD1.  
 
Sequencing of the FC gamma receptor gene sequences in patients, such as the 
introns, exons and promoter sequences could identify further variants that may cause 
susceptibility to SLE in this population. As discussed, epigenetics plays a role in SLE. 
Methylation and acetylation studies could be applied to see the role epigenetics plays 
within this population and SLE.  
 
Finally, the clinical and immunologic data could be further investigated in its link to 
the genetic results. Molecular and clinical studies are often separated but with future 
research these two components could be studied together in order to confidently 
identify an association. 
 
 
Conclusion 
 
This study focused on the genotypes of two SNPs (rs396991 and rs10127939) and 
the neutrophil-antigen allotypes as well as the copy number variation within the 
genes FCGRIIIA and FCGRIIIB. The methods were performed on DNA from both 
SLE cases and matching controls. In South Africa there is a paucity of data relating to 
the genetic mechanism of SLE in black South Africans. This study helps in further 
understanding the genetic basis of this disease in this population. 
 
It was found that the allotypes, SNPs and copy number variation statistically do not 
confer susceptibility to SLE in this Black South African patient cohort. However, it 
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was found that NA1/NA2 is statistically significant in conferring susceptibility to LN in 
this cohort, which is a major cause of death in this population. 
 
Clinical variables were investigated and it was noteworthy that 43.8% of patients had 
LN and 23.5% of patients were recorded to have had previous TB infection. This 
again highlights the need to treat infections timeously and for there to be accurate 
diagnosis of LN. Other immunologic and clinical criteria were also examined and they 
were found to be in line with values seen in previous studies in South Africa. This 
study emphasises the need for further research of SLE genetics in this unique study 
cohort. 
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Appendix B- Information and Consent Forms 
 
INVITATION TO PARTICIPATE IN A STUDY ON SYSTEMIC LUPUS 
ERYTHEMATOSUS GENETICS 
Patient Information Sheet 
 
Dear Sir/Madam, 
My name is Wesley Tulleken. You have been diagnosed with systemic lupus erythematosus (SLE) 
and I would like to invite you to take part in a study that we are doing in the Rheumatology Clinic at 
Chris Hani Baragwanath Academic Hospital. We are investigating the role of genetic factors in Black 
South African patients who have SLE. We plan to look at five genetic regions (rs1143679, rs3131379, 
rs132771130, rs10516487 and rs4963128) in your DNA. In the future, we would like to look at other 
genetic regions associated with SLE (about 200 000 sites). This will allow us to better understand the 
causes of this very complex disease. 
The study will not involve any costs to you and participation is completely voluntary. You can withdraw 
at any time, and you will not be disadvantaged in any way if you refuse. Non-participation will not 
result in any prejudice of clinical management or treatment. Participation in the study does not 
advantage you in any way. You will receive treatment as normal. 
If you agree to take part in the study, we will do a clinical examination, take 15ml (3 teaspoons) of 
blood for the DNA studies and document which antibodies you have, and if you have kidney problems 
from SLE. This procedure may result in discomfort and pain but the procedure is short and the pain 
and discomfort will not linger afterwards. The blood sample will be stored for ten (10) years and may 
be used for further genetic studies on SLE in the future. The samples will be anonymously labelled 
and will be stored in the Division of Human Genetics, National Health Laboratory Service. Any further 
studies other than the current study using your DNA will need to reapply for ethics approval. The 
results of the study will be handled confidentially and used by me and my fellow researchers solely for 
research purposes. We plan to publish the results in a medical journal. We will not publish anything 
identifying any study participant.  
This study has been approved by the Human Research Ethics Committee at the University of the 
Witwatersrand. 
 
If you would like more information or would like to withdraw from the study, please contact me or the 
following doctors 
 
Dr W. Tulleken      Professor Mohammed Tikly 
083 311 5076      (011) 933-9577  
Chris Hani Baragwanath Hospital    Chris Hani Baragwanath Hospital  
University of the Witwatersrand                 University of the Witwatersrand  
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Professor Peter Cleaton-Jones 
Chairman of the Human Research Ethics Committee  
University of the Witwatersrand  
(011) 717-2301 
 
INFORMED CONSENT TO PARTICIPATE IN A STUDY ON SYSTEMIC 
LUPUS ERYTHEMATOSUS GENETICS 
 
You have been asked to participate in a research study which will look at the genetics of systemic 
lupus erythematosus (SLE). 
 
Have you been informed about the purpose of the study?  YES  NO 
Have you been informed about the procedures involved in the study? YES  NO 
Do you agree and consent to give a blood sample for use in the study? YES  NO 
Do you understand that the results will not be made available to you? YES  NO 
Do you agree and consent to having your blood sample stored for 10 years?  YES              NO 
 
 
The research study, including all information, has been described to me. I understand 
what my involvement in the study means and I voluntarily agree to participate.  
 
 
Full name of participant:          
 
 
Signature of Participant:          
 
 
Date:    
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Appendix C- Table showing the Allele and Genotype Frequencies of rs396991 And Allotypes NA1/NA2 
 
 LN 
(n=71) 
Non-LN 
(n=91) 
OR 
(95% 
CI) 
p- 
value 
Overall 
cases 
(n=162) 
Controls 
(n=155) 
OR 
(95% CI) 
p-value 
T 0.31 0.28  
1.121 
(0.693-
1.813) 
 
 
0.643 
0.32 0.35  
1.135 
(0.811-
1.588) 
 
 
0.654 
G 0.69 0.72 0.68 0.65 
TT 8.9% (6) 7.8% (7) 11% (18) 12% (19) 
TG 44.7% (32) 42.5% (39) 42% (68) 47% (73) 
GG 46.3% (33) 49.7% (45) 47% (76)  41% (63) 
NA1 0.73 0.59  
 
1.879 
(1.109-
3.184) 
 
 
 
0.018 
0.69 0.63  
 
1.281 
(0.902-
1.817) 
 
 
 
0.166 
NA2 0.27 0.41 0.31 0.37 
Null Allele 0.22 0.07   
NA1/NA1 43% (30) 44% (40) 49% (80) 38% (59) 
NA1/NA2 26.6% (19) 21.6% (20) 28% (45) 49.5% (77) 
NA2/NA2 7% (6) 27.03% (25) 15% (24) 12% (18) 
Null/null 22.4% (16) 7.37% (6) 8% (13) 0.5% (1) 
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Appendix D- Demographic and Clinical Data of the SLE Patients 
 
SLE # Gender Age  
Age of 
Onset SLICC LN LN I LN II LN III 
LN 
IV LN V TB 
↓ C3 and 
C4 
Anti-
dsDNA 
Anti- 
Sm 
SLE001 F 69 63 9 0 0 0 0 0 0 1 1 0 1 
SLE002 F 44 27 4 0 0 0 0 0 0 1 0 0 0 
SLE003 F 26 24 7 0 0 0 0 0 0 0 0 0 0 
SLE004 F 39 32 6 0 0 0 0 0 0 0 0 0 1 
SLE007 F 22 21 13 1 0 1 0 0 0 0 1 0 1 
SLE008 F 20 16 11 1 0 0 0 0 1 0 1 1 1 
SLE009 F 45 41 4 0 0 0 0 0 0 0 1 0 0 
SLE010 F 50 31 9 1 0 0 0 0 1 1 1 1 0 
SLE011 M 30 25 7 0 0 0 0 0 0 1 1 1 1 
SLE012 F 42 33 6 0 0 0 0 0 0 0 1 0 0 
SLE013 F 39 38 7 0 0 0 0 0 0 0 1 0 1 
SLE014 F 26 25 10 1 0 0 1 0 0 0 1 1 0 
SLE015 F 29 29 6 0 0 0 0 0 0 0 0 0 1 
SLE016 F 58 50 6 0 0 0 0 0 0 0 1 0 1 
SLE017 F 46 44 8 0 0 0 0 0 0 0 1 0 1 
SLE019 F 32 31 6 1 0 0 0 0 1 0 1 0 1 
SLE020 F 24 24 8 1 0 0 0 0 1 1 1 0 1 
SLE021 F 26 23 8 0 0 0 0 0 0 0 1 1 1 
SLE022 F 32 29 7 0 0 0 0 0 0 0 1 1 0 
SLE023 F 29 15 10 1 0 0 1 0 0 0 1 1 1 
SLE025 F 34 27 10 0 0 0 0 0 0 1 1 0 1 
SLE026 F 67 56 4 0 0 0 0 0 0 0 0 0 1 
SLE027 F 55 52 5 0 0 0 0 0 0 1 0 0 0 
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SLE028 F 54 49 6 0 0 0 0 0 0 0 1 0 0 
SLE029 F 41 34 8 0 0 0 0 0 0 0 1 0 1 
SLE030 F 30 28 6 0 0 0 0 0 0 0 1 0 1 
SLE031 F 44 33 6 0 0 0 0 0 0 0 1 1 0 
SLE032 F 43 41 9 0 0 0 0 0 0 0 1 0 1 
SLE033 F 35 24 12 0 0 0 0 0 0 1 1 1 1 
SLE035 F 56 46 4 0 0 0 0 0 0 1 0 0 0 
SLE036 F 28 27 9 0 0 0 0 0 0 0 1 0 1 
SLE037 F 30 27 11 1 0 0 0 0 1 0 1 1 1 
SLE038 F 31 23 10 1 0 0 0 0 0 1 1 0 1 
SLE039 F 19 19 5 1 0 0 0 1 0 0 1 0 0 
SLE040 F 28 22 9 1 0 1 0 0 0 0 0 0 0 
SLE041 M 27 21 8 1 0 0 0 0 1 0 1 1 1 
SLE042 F 33 32 4 0 0 0 0 0 0 0 0 0 0 
SLE043 F 57 34 5 0 0 0 0 0 0 0 0 0 0 
SLE046 F 56 36 9 0 0 0 0 0 0 1 1 1 0 
SLE047 F 23 14 9 0 0 0 0 0 0 1 1 1 1 
SLE048 F 46 38 11 0 0 0 0 0 0 0 1 1 1 
SLE049 F 34 28 4 0 0 0 0 0 0 0 1 1 0 
SLE050 F 23 22 7 1 0 0 0 1 0 1 1 1 1 
SLE051 F 35 35 8 0 0 0 0 0 0 0 0 0 1 
SLE052 F 36 29 9 0 0 0 0 0 0 0 1 0 1 
SLE053 F 25 22 9 0 0 0 0 0 0 0 1 0 1 
SLE054 F 24 23 12 0 0 0 0 0 0 0 1 0 1 
SLE056 M 19 18 14 1 0 0 0 0 1 0 1 1 1 
SLE057 F 57 54 8 0 0 0 0 0 0 0 0 1 1 
SLE058 F 43 38 8 1 0 0 0 0 0 1 1 0 1 
SLE060 F 39 23 10 0 0 0 0 0 0 0 1 1 0 
SLE061 F 24 19 9 1 0 0 1 0 0 1 1 1 1 
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SLE062 F 36 34 5 1 0 0 1 0 1 0 0 0 1 
SLE063 F 43 32 10 0 0 0 0 0 0 1 1 0 1 
SLE064 F 74 50 4 0 0 0 0 0 0 0 0 0 0 
SLE066 F 29 29 8 1 0 1 0 0 0 0 1 1 1 
SLE067 F 54 37 4 0 0 0 0 0 0 0 1 0 0 
SLE068 F 31 25 11 1 0 0 0 0 1 0 1 0 1 
SLE069 F 44 40 9 1 0 0 1 0 0 0 1 1 0 
SLE070 F 27 21 8 1 0 0 0 0 1 1 1 1 0 
SLE071 M 43 38 7 0 0 0 0 0 0 1 1 0 1 
SLE072 F 24 21 13 1 0 0 1 0 0 1 1 1 0 
SLE076 F 67 61 7 0 0 0 0 0 0 0 0 0 1 
SLE078 F 32 29 8 1 0 0 0 1 0 0 1 1 1 
SLE079 F 40 31 6 0 0 0 0 0 0 0 0 0 0 
SLE081 F 51 34 12 1 0 0 0 0 1 0 1 1 1 
SLE083 M 40 37 4 0 0 0 0 0 0 0 1 0 1 
SLE084 F 27 22 9 0 0 0 0 0 0 0 1 1 1 
SLE085 F 38 38 12 1 0 0 0 0 1 0 1 1 1 
SLE086 F 39 33 10 0 0 0 0 0 0 0 1 1 1 
SLE087 F 24 24 9 1 0 1 0 0 0 0 1 1 1 
SLE088 F 59 41 13 0 0 0 0 0 0 0 1 1 1 
SLE089 M 35 15 13 1 0 1 0 0 0 0 1 1 1 
SLE091 F 23 13 7 0 0 0 0 0 0 0 0 0 1 
SLE092 F 37 35 7 0 0 0 0 0 0 0 1 0 1 
SLE094 F 39 38 8 1 0 0 1 0 0 1 1 0 1 
SLE095 F 31 30 12 1 0 0 1 0 0 0 1 0 1 
SLE097 F 55 49 12 0 0 0 0 0 0 1 1 1 1 
SLE098 F 29 25 11 1 0 0 1 0 0 0 1 1 1 
SLE099 F 42 40 4 1 0 0 0 0 1 0 0 0 1 
SLE100 M 46 46 6 0 0 0 0 0 0 1 1 0 1 
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SLE101 F 37 37 7 1 1 0 0 0 0 0 1 0 1 
SLE102 F 37 37 11 1 0 1 0 0 1 0 1 1 1 
SLE103 F 44 31 9 1 0 0 0 0 1 0 1 0 1 
SLE104 F 56 32 9 0 0 0 0 0 0 0 1 1 1 
SLE106 F 55 46 4 1 0 0 0 0 1 0 0 0 0 
SLE107 F 32 25 7 0 0 0 0 0 0 1 0 1 1 
SLE108 F 33 33 8 1 0 0 0 0 1 0 1 0 1 
SLE109 F 20 20 8 1 0 0 1 0 0 1 1 0 1 
SLE113 F 56 40 8 0 0 0 0 0 0 1 1 0 0 
SLE114 F 28 16 10 0 0 0 0 0 0 0 1 1 1 
SLE116 F 35 21 12 1 0 0 0 0 1 0 1 1 1 
SLE118 F 33 25 6 0 0 0 0 0 0 0 0 0 0 
SLE122 F 27 26 9 0 0 0 0 0 0 0 1 0 1 
SLE123 F 17 17 9 1 0 0 0 0 1 0 1 1 1 
SLE124 F 46 29 11 1 0 0 0 0 1 1 1 0 1 
SLE125 F 63 58 5 0 0 0 0 0 0 0 0 0 1 
SLE127 F 16 15 8 0 0 0 0 0 0 0 1 1 1 
SLE128 F 36 33 9 1 0 0 1 0 0 0 1 0 1 
SLE129 F 20 11 10 1 0 0 0 0 1 0 1 1 0 
SLE130 F 53 51 7 1 0 0 0 1 0 0 1 0 1 
SLE131 F 65 61 4 0 0 0 0 0 0 1 0 0 1 
SLE132 F 51 38 4 0 0 0 0 0 0 0 0 0 0 
SLE133 M 69 54 8 0 0 0 0 0 0 0 0 0 1 
SLE134 F 44 28 11 1 0 0 0 0 1 1 1 0 1 
SLE135 F 31 28 9 0 0 0 0 0 0 0 1 1 1 
SLE136 F 33 26 7 0 0 0 0 0 0 0 1 0 1 
SLE137 F 22 19 7 0 0 0 0 0 0 0 1 0 1 
SLE138 F 39 30 5 1 0 0 0 0 1 0 1 1 0 
SLE139 F 42 42 10 0 0 0 0 0 0 0 1 0 1 
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SLE140 F 20 20 4 0 0 0 0 0 0 0 0 0 1 
SLE141 F 51 41 9 0 0 0 0 0 0 1 0 0 1 
SLE142 F 25 17 8 0 0 0 0 0 0 0 1 0 1 
SLE145 M 35 33 5 1 0 0 0 1 0 0 1 0 1 
SLE146 F 44 40 8 1 0 0 0 0 1 0 1 0 1 
SLE147 F 54 48 5 1 0 0 0 0 1 0 0 0 0 
SLE148 F 43 29 5 0 0 0 0 0 0 0 1 0 0 
SLE151 F 41 41 6 1 0 0 0 0 0 1 0 0 0 
SLE152 F 28 28 11 1 0 0 0 1 0 0 1 1 1 
SLE153 F 34 34 9 0 0 0 0 0 0 0 1 1 1 
SLE156 F 76 53 11 0 0 0 0 0 0 0 1 1 0 
SLE160 F 29 23 12 0 0 0 0 0 0 0 1 1 1 
SLE161 F 41 38 10 0 0 0 0 0 0 1 1 1 1 
SLE162 F 59 43 6 1 0 0 1 0 0 0 0 1 1 
SLE165 F 56 56 4 0 0 0 0 0 0 0 0 0 0 
SLE166 F 60 39 9 0 0 0 0 0 0 0 1 1 1 
SLE167 F 38 33 10 0 0 0 0 0 0 0 1 1 1 
SLE169 F 23 21 8 0 0 0 0 0 0 0 1 0 1 
SLE170 F 59 50 7 0 0 0 0 0 0 0 0 0 0 
SLE171 F 53 52 11 0 0 0 0 0 0 0 1 0 1 
SLE172 F 66 42 5 0 0 0 0 0 0 0 1 0 0 
SLE173 F 60 42 8 0 0 0 0 0 0 0 1 1 1 
SLE174 F 46 23 5 0 0 0 0 0 0 0 1 0 0 
SLE175 F 41 30 10 0 0 0 0 0 0 1 1 0 1 
SLE176 F 41 19 14 1 0 0 1 0 0 0 1 1 1 
SLE177 F 46 45 7 0 0 0 0 0 0 0 1 0 1 
SLE178 F 41 41 6 0 0 0 0 0 0 0 0 0 1 
SLE179 M 21 21 9 1 0 0 1 0 0 1 1 1 0 
SLE180 F 37 33 10 1 0 0 1 0 0 0 1 1 1 
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SLE 182 F 30 24 12 1 0 0 1 0 1 0 1 1 1 
SLE 183 F 38 27 10 1 0 0 0 0 1 1 1 1 0 
SLE 184 F 31 25 11 1 0 0 0 1 0 1 1 1 0 
SLE 185 F 14 14 7 1 1 0 0 0 0 0 1 0 1 
SLE 187 F 39 39 10 1 0 0 1 1 0 1 1 0 1 
SLE 189 F 34 23 10 1 0 0 1 0 1 0 1 1 1 
SLE 190 F 34 25 9 1 0 1 0 0 1 0 1 1 1 
SLE 191 F 43 30 4 0 0 0 0 0 0 0 0 1 0 
SLE 192 F 34 23 9 1 0 0 0 0 1 0 0 1 1 
SLE 193 F 50 32 4 0 0 0 0 0 0 1 1 0 0 
SLE 194 F 36 27 11 0 0 0 0 0 0 1 1 1 1 
SLE 195 F 43 38 6 0 0 0 0 0 0 0 0 1 1 
SLE 196 F 54 54 5 0 0 0 0 0 0 0 0 0 1 
SLE 197 F 59 46 9 1 0 0 0 0 1 0 0 0 1 
SLE 198 F 39 34 6 1 0 0 1 0 0 0 0 0 0 
SLE 199 M 54 48 8 0 0 0 0 0 0 0 1 1 1 
SLE 200 F 15 13 6 0 0 0 0 0 0 0 0 0 1 
SLE 201 F 54 42 6 0 0 0 0 0 0 0 0 0 1 
SLE 202 F 21 19 10 1 1 0 0 0 0 0 0 0 1 
SLE 203 F 22 21 9 1 0 0 1 0 0 0 1 1 1 
SLE 204 M 30 30 5 0 0 0 0 0 0 0 0 0 1 
SLE205 F 17 17 7 1 1 0 0 0 1 1 0 0 1 
SLE206 F 30 30 10 0 0 0 0 0 0 0 1 1 1 
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